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This dissertation consists of three essays on the economics of dairy nutrition and disease control, 
in particular, productivity and profitability associated with the dairy industry. The first essay 
examines the effect of a dairy feed supplement on milk production and profitability of dairy 
operations. The second essay develops a conceptual model for examining infectious disease 
control in livestock using Mycobacterium avium ssp. paratuberculosis (MAP) and Johne’s 
disease (JD) control in dairy herds as an example. The third essay looks into the economic and 
epidemiological consequences of current and next generation vaccines for MAP and JD in dairy 
herds.  
 Chapter 1 examines the profitability of rumen-protected methionine (RPMet) supplement 
on milk protein production. The additional daily profit per cow potentially earned by adding 
various amounts of RPMet supplement to the diet of lactating cows is analyzed and reported. The 
optimal amount of RPMet reported to maximize daily profit per cow is compared to the RPMet 
required to maximize milk protein production. These optimal quantities are very similar given 
current prices for RPMet and milk protein. 
 Chapter 2 presents a conceptual framework for evaluating the economics of infectious 
disease control for livestock. An animal compartment model is used to develop a conceptual 
model that incorporates the complexity inherent in disease-specific epidemiology in livestock. 
This conceptual model is empirically applied with a discrete optimal control model maximizing 
  
 
net present value to evaluate the economic and epidemiological consequences of various control 
strategies for MAP, the pathogen causing Johne's disease in dairy herds. 
Chapter 3 investigates the epidemiological impacts and economic values of hypothetical 
MAP vaccines in dairy herds. Scenarios for the potential epidemiological impacts of MAP 
vaccines are created, and then economically justifiable values are estimated at which they would 
be cost-effective to dairy producers. The estimated economic values of MAP vaccines suggest 
that some vaccinations can be an economically attractive method of MAP control for dairy 
producers. 
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CHAPTER 1 
AN OPTIMAL APPLICATION OF RUMEN-PROTECTED METHIONINE SUPPLEMENT 
FOR MAXIMIZING MILK PROTEIN PRODUCTION AND PROFIT IN DAIRY HERDS 
 
Abstract 
The profitability of feeding rumen-protected Met (RPMet) sources to produce milk protein is 
estimated using a two-step procedure: First, the effect of Met in metabolizable protein (MP) on 
milk protein production is estimated by using a quadratic Box-Cox functional form. Then, 
utilizing these estimation results, the amounts of RPMet supplement that corresponds to the 
optimal levels of Met in MP for maximizing milk protein production and profit on dairy farms 
are determined.  
The data used in this study are modified from data used to determine the optimal level of 
Met in MP for lactating cows in the National Research Council publication Nutrient 
Requirements of
 
Dairy Cattle (NRC, 2001). The data used in this study differ from that in the 
NRC (2001) in two ways. First, as dairy feed generally contains 1.80-1.90% Met in MP, this 
study adjusts the reference production value (RPV) from 2.06 to 1.80 or 1.90%. Consequently, 
the milk protein production response is also modified to a RPV of 1.80 or 1.90% Met in MP. 
Second, as this study is especially interested in how much additional Met, beyond the 1.80 or 
1.90% already contained in the basal diet is required to maximize farm profits, the data used are 
limited to concentrations of Met in MP above 1.80 or 1.90%. This allowed us to calculate any 
additional cost to farmers based solely on the price of an RPMet supplement, and eliminates the 
need to estimate the dollar value of each gram of Met already contained in the basal diet.  
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Results indicate that the optimal level of Met in MP for maximizing milk protein 
production is 2.40 percent and 2.42%, where the RPV is 1.80 and 1.90%, respectively. These 
optimal levels are almost identical to the recommended level of Met in MP of 2.40% in the NRC 
(2001). The amounts of RPMet required to increase the percentage of Met in MP from each RPV 
to the 2.40 and 2.42% are 21.6 and 18.5 g/d, respectively. On the other hand, the optimal level of 
Met in MP for maximizing profit is 2.32 and 2.34%, respectively. The amounts of RPMet 
required to increase the percentage of Met in MP from each RPV to the 2.32 and 2.34% are 18.7 
and 15.6 g/d, respectively. In each case, the additional daily profit per cow is estimated to be 
$0.38 and $0.29. These additional profit estimates are $0.02 higher than the additional profit 
estimates for maximizing milk protein production.  
 
Introduction  
Dairy farmers in New York State (NYS) and most regions of the U.S. presently receive payment 
for their milk under the Federal Milk Marketing Order multiple-component pricing system. 
Payment is based on the quantities of milk components such as butterfat, protein, and other 
solids. Of these components, milk protein is the most valuable for dairy farmers. Its price is the 
highest of all other milk components, having significantly increased over the last seven years 
(Figure 1.1). This has led to great interest among dairy farmers in increasing milk protein 
production in order to increase profits.  
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Figure 1.1. Average producer prices for milk components over the last seven years (2000-2006) 
based on the producer component price data provided by the northeast marketing area of 
agricultural marketing service, U.S. Department of Agriculture 
 
There are several possible ways to increase milk protein production. These include 
genetic improvement (Gibson, 1989; McAllister et al., 1990; Hansen et al., 2002), switching 
breeds (Elbehri et al., 1994; Bailey et al., 2005), and modifying the diets of lactating dairy cows. 
As genetic improvement of cows is a lengthy and difficult process for individual farmers, and 
switching breeds is expensive, increasing milk protein output through dietary means is the most 
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practical short-term option. Of the various ways to do this, balancing amino acids (AA) in the 
dairy cows’ diet is the most convenient way to enhance milk protein production because it can be 
simply accomplished by providing additional AA supplements to cows.  
Of the essential AA in lactating dairy cows, Lysine (Lys) and Methionine (Met) are the 
two most limiting for the synthesis of milk and milk protein (Schwab et al., 1976), and Lys and 
Met are often deficient in diets fed to lactating dairy cattle. Thus, several studies summarized in 
the National Research Council publication Nutrient Requirements of
 
Dairy Cattle (NRC, 2001) 
have examined the relationship between post-ruminal supply of Lys or Met and milk protein 
production, and found that increasing the post-ruminal supply of Lys or Met increases milk 
protein production (NRC, 2001). Although the different effect of Lys or Met on milk production 
reported in several studies depends on the differences in the status of Lys, Met, other AA, 
genetic traits, or the lactation status of the cows, many studies also reported that providing a 
dietary supplement of rumen-protected Lys (RPLys) or rumen-protected Met (RPMet) increases 
milk protein production (NRC, 2001; Misciattelli et al., 2003; Socha et al., 2005; Rulquin et al., 
2006). This increase is mainly accomplished by increasing casein in milk, the main ingredient of 
cheese (Donkin et al., 1989; Chow et al., 1990; Armentano et al., 1993). Thus, increasing milk 
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protein production by adding an RPMet supplement to the diet of lactating cows is beneficial for 
not only dairy farmers but also cheese manufacturers.  
According to the NRC (2001), the estimated optimal level of concentration of Lys and 
Met in metabolizable protein (MP) for the combined functions of maintenance and milk protein 
production is approximately 7.2 and 2.4%, respectively. However, typical dairy lactating feed in 
NYS contains > 6.65 percent Lys and 1.8-1.9 percent Met, more than 92% of the Lys levels but 
only 75%-79% of the Met levels suggested by the NRC (2001). Thus, dairy farmers may be able 
to increase milk protein production simply by adding an RPMet supplement to the diet of 
lactating cows. However, dairy farmers are reluctant to do this because there are presently no 
studies available on the economic benefits associated with providing this supplement. Therefore, 
this study examines the profitability of RPMet supplement on milk protein production using the 
following two-step procedure: First, the effect of Met in MP on milk protein production is 
estimated using a quadratic Box-Cox functional form (QBC). Then, utilizing these estimation 
results, the amounts of RPMet supplement which correspond to the optimal levels of Met in MP 
for maximizing milk protein production and profit on dairy farms are determined.  
 
Materials and methods  
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Quadratic Box-Cox functional form 
 The choice of functional form is not a trivial task in applied economic data analysis. 
Although there are some popular forms, such as translog, quadratic, and Cobb-Douglas, which 
are frequently used in production analyses, there is no straightforward statistical test to determine 
which functional form is superior. Thus, in many cases, researchers choose a functional form 
according to their research purposes and statistical limitations imposed by their data. 
Because this research entails a single-output and single-input production relationship, the 
Box-Cox transformation (Box and Cox, 1964) with a quadratic functional form is particularly 
useful to determine the most appropriate functional form. There are several reasons for this. First, 
the Box-Cox transformation requires no prior restrictions on estimating such a production 
relationship, so the estimated value of the transformation parameters describes the functional 
form that best fits the data. Second, this transformation results in less heteroscedastic residuals 
than those from the untransformed data (Box and Cox, 1964). Third, the QBC incorporates first-
order and second-order effects of an input on output. Thus, the QBC has great flexibility. Finally, 
the QBC contains several traditional functions such as quadratic, translog, and inverse quadratic 
as special embedded parametric cases, and the validity of these functions can be tested by the 
likelihood ratio test. This reduces the effort in selecting the underlying functional form for a 
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given set of data. Thus, this study utilized the following QBC to estimate the relationship 
between the percentage of milk protein and Met in MP. 
The QBC used in this study can be expressed as:  
 
( ) ( ) ( ) ( )
0 1 2i i i i iy x x x
           (1.1) 
where the subscript i indexes individual observation,
 i
y  is the milk protein content response
1
,
 
ix  is the percentage of Met in MP, 0 , 1 , and 2  are parameters to be estimated,   is the Box-
Cox transformation parameter to be estimated, and i is the residual which is assumed to be 
normally distributed with zero mean and constant variance σ2. The term )(
iy  is the Box-Cox 
transformation  /)1( iy , and 
)(
ix  
is the Box-Cox transformation  /)1( ix , which are 
transformed with the common parameter  that can assume any value. Specifically, when the 
estimated value of   approaches one, Equation (1.1) is reduced to the quadratic function, when 
  approaches zero, Equation (1.1) is reduced to the translog function, and when   approaches 
minus one, Equation (1.1) is reduced to the quadratic function with inverse specification. 
In this study, the amount of feed consumed by each treatment group varied from 
experiment to experiment. Thus, if the selected dependent and independent variables in the QBC 
are those expressed on a quantity basis (g/d), the estimation result of the effect of Met in MP on 
                                                 
1
 Production response expressed as a percentage at each level of Met in MP relative to a reference production value. 
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milk production will be over estimated. Therefore, this study measured the response effect using 
variables expressed as percentage of milk protein, and the percentage of Met in MP, as was done 
in the NRC (2001). This specification minimizes the effects of other nutritional factors on milk 
protein production caused by the different level of feed consumption in each experiment. 
The transformation parameter  in the QBC was estimated by the maximum likelihood 
estimation technique using the computer software STATA because the QBC is non-linear in its 
parameters. However, in the presence of heteroscedastic residuals, estimating the Box-Cox 
regression model can generate misleading results (Seaks and Layson, 1983; Blaylock and 
Smallwood, 1985). Due to the complexity of the maximum likelihood estimation technique for 
estimating the Box-Cox-type models, the majority of empirical analyses employing this 
estimation technique did not test significantly for heteroscedasticity, and the majority of 
statistical software programs also do not provide any test for identifying such an econometric 
problem. Therefore, in this study, the QCB was re-estimated by the ordinary least square 
estimator after modifying the data with the estimated parameter   in order to test 
heteroscedasticity by the Breusch-Pagan test. 
If heteroscedasticity exists, the models should be either modified as the QBC with a Just-
Pope risk specification in a mean-variance framework (Just and Pope, 1978), or re-estimated by 
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using alternative estimation techniques such as the Box-Cox with a weighted-least-squares 
correction for heteroscedasticity (Seaks and Layson, 1983). A Just-Pope specification would be 
especially useful since it allows formulating the heteroscedastic residuals as an inherent risk in 
the production function.  
 
Optimal RPMet application 
When a single-output and single-input are measured on a quantity basis such as grams per 
day, and output is represented as a continuously differentiable function of input, the producer’s 
strategy for maximizing profit is simply a matter of choosing the appropriate input level. If such 
a function is concave, the optimal level of input is determined to be the point at which the 
marginal product of input equals the ratio of a given input price and output price. However, this 
producer’s strategy for maximizing profit described above cannot be directly applied to this 
study because the selected output and input in Equation (1.1) are expressed as percentages. 
Therefore, this study used a different profit maximization method to determine the optimal 
application levels of RPMet supplement corresponding to the optimal levels of Met in MP for 
maximizing milk protein production and profit on dairy farms.  
The first derivative of the quadratic Box-Cox functional form is 
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(1/ ) 1
2 2 1
2 (1 )/
2 1 2 2 1 0
/ (2 2 )
[ ( 2 ) ( 1)]
i i i i
i
dy dx x x
x x
  
   
    
        
 
 
  
     
 (1.2) 
In this study, this derivative represents the elasticity of protein production at a certain percentage 
of Met in MP ( ix ), that is, how much the percentage of milk protein increased or decreased when 
small changes were made in a certain percentage of Met in MP ( ix ). Thus, the optimal 
percentage of Met in MP for maximizing milk protein production is simply the point where the 
output elasticity, the first derivative of the estimated QBC, equals zero and begins to be negative.  
 The optimal level of Met in MP for maximizing profit is calculated according to the 
following steps: i) define the reference production value (RPV) of Met in MP ( 0x ) according to 
the general level of Met in MP in typical dairy lactating rations in NYS such as 1.80 or 1.90, ii) 
set the base production and input level corresponding to the RPV ( 0x ) as the amount (g/d) of 
base milk protein (
0x
y ) and the amount (g/d) of base Met (
0x
Met ), iii) calculate the amount (g/d) 
of additional milk protein (
ix
y ) when the percentage of Met in MP changes from the RPV ( 0x ) to 
a certain percentage of Met in MP ( ix ). To obtain the amount (g/d) of additional milk protein 
(
ix
y ), first, rearrange the deterministic part of the QBC in Equation (1.1), and multiply this by 
the amount (g/d) of base milk protein (
0x
y ) as 
 
0
2 1/[{( (( 1) / ) (( 1) / ) ) 1}]
ix i i x
y c b x a x y            (1.3)
 iv) calculate the amount (g/d) of additional Met required (
ix
Met ) when the percentage of Met in 
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MP changes from the RPV ( 0x ) to a certain percentage of Met in MP ( ix ). Because the 
difference between a certain percentage of Met in MP ( ix ) and the RPV ( 0x ) is 
[ 100)}/()/(){(
00000
 xxxxxxi MPMetMetMPMetMetxx ii ], the amount (g/d) of 
additional Met required (
ix
Met ) can be written as 
 
0 0 0 0
2
0 0{( ) }/{( ) 100( )}ix i x i x x xMet x x MP x x MP Met MP      (1.4) 
 where 
0/00 xMetMP xx   is the amount (g/d) of total MP at the RPV ( 0x ). 
v) calculate the amount (g/d) of RPMet required (
ix
RPMet ) when the percentage of Met in MP 
changes from the RPV ( 0x ) to a certain percentage of Met in MP ( ix ) as 
 /
i ix x
RPMet Met TIAMet  (1.5) 
where TIAMet  is the total intestinal availability of an RPMet supplement, which is calculated as 
the ruminal escape rate multiplied by the intestinal digestibility of the RPMet supplement. 
vi) calculate the additional (cumulative) daily revenue per cow (
ix
R ) when the percentage of Met 
in MP changes from the RPV ( 0x ) to a certain percentage of Met in MP ( ix ) as  
 Pri ix x otR y P   (1.6) 
where otPPr  is a milk protein price per gram. 
vii) calculate the additional (cumulative) daily cost per cow (
ix
C ) when the percentage of Met in 
MP changes from the RPV ( 0x ) to a certain percentage of Met in MP ( ix ) as  
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i ix x Met
C RPMet P   (1.7) 
where MetP  is a milk protein price per gram. 
viii) calculate the additional (cumulative) daily profit per cow (
ix
 ) when the percentage of Met 
in MP changes from the RPV ( 0x ) to a certain percentage of Met in MP ( ix ) as  
 
i i ix x x
R C    (1.8) 
ix) determine the amount (g/d) of RPMet required when the percentage of Met in MP changes 
from the RPV ( 0x ) to the percentage of Met in MP where the calculated additional (cumulative) 
daily profit per cow is the maximum by incrementally changing the input using the spread sheet 
software Excel. 
 
Data 
The data used in this study were modified from the database used to determine the 
optimal level of Met in MP for lactating cows in the NRC (2001). These data were collected 
from several existing studies and contain 28 experiments, conducted solely on the Holstein breed, 
with 87 treatments in which Met was infused continuously into the cow’s abomasum or 
duodenum, or fed in ruminally protected form (Table 1.1). The data used in this study differ from 
that in the NRC (2001) in two ways. First, as NYS dairy feed generally contains 1.80-1.90 
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percent Met in MP, this study adjusted the RPV from 2.06 to 1.80 or 1.90 percent. Consequently, 
the milk protein production response is also modified to a RPV of 1.80 or 1.90 Met in MP. 
Second, as this study is especially interested in how much additional Met, beyond the 1.80 or 
1.90 percent already contained in the basal diet is required to maximize farm profits, the data 
used were limited to concentrations of Met in MP above 1.80 (48 observations) or 1.90 (40 
observations) percent. Because the data used in the NRC (2001) contain observations which have 
significantly less Met in MP percent than RPV of 1.90, these observations (8 observations) are 
deleted when estimating the QBC where RPV is 1.90 percent. This allows us to calculate any 
additional cost to farmers based solely on the price of an RPMet supplement, and eliminates the 
need to estimate the dollar value of each gram of Met already contained in the basal diet.  
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Table 1.1. Studies used to determine the dose-response relationships for Lysine and Methionine 
in Metabolizable Protein (Source: National Research Council. 2001. Nutrient Requirements of 
Dairy Cattle. 7th rev. ed. National Academies Press, Washington, DC) 
Armentano et al. (1997) Rulquin and Delaby (1994) 
Casper et al. (1987) Rulquin et al. (1994) 
Casper and Schingoethe (1988) Schingoethe et al. (1988) 
Illg et al. (1987) Schwab et al. (1976) 
Munneke  et al. (1991) Schwab et al. (1992a) 
Papas et al. (1984a) Schwab et al. (1992b) 
Papas et al. (1984b) Socha (1994) 
Pisulewski et al. (1996) Socha et al. (1994a) 
Polan et al. (1991) Socha et al. (1994b) 
Rogers et al. (1987) Yang et al. (1986) 
Rulquin and Delaby (1997)  
 
As in the NRC (2001), this study also used only the restricted Met experiment data in 
which Lys was 6.50 percent or more of MP in order to examine the production relationship 
between milk protein and Met in MP because low concentrations of Lys in MP limited milk 
protein responses to Met in MP. Total intestinal availability of Met (TIAMet), which is 
calculated as the ruminal escape rate multiplied by the intestinal digestibility of supplemental 
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Met, was used to represent the contribution of supplemental Met to predicted flows of digestible 
Met originating from the basal diet. In the NRC (2001), the TIAMet of infused Met is considered 
to be 100 percent, and the TIAMet of all RPMet products is calculated to be 81 percent 
(0.90×0.90).  
In this study, the final data set (containing 48 observations) where the RPV is 1.80 
percent showed an average 
0x
Met  is 41.55 grams per day per cow, an average 
0x
MP  is 2308.23 
grams per day, and an average 0y  is 1052.25 grams per day. On the other hand, the final data set 
(containing 40 observations) in which the RPV is 1.90 percent showed an average 
0x
Met  is 43.27 
grams per day, an average 
0x
MP  is 2277.56 grams per day, and an average 0y  is 1047.46 grams 
per day. 
 
Results and discussion 
Tables 1.2 and 1.3 report the estimated QBCs where the RPV is 1.80 percent and 1.90 percent, 
respectively. The values of the estimated parameters are different because the RPV and the 
number of observations in each model are different. After estimating both of the QBCs by the 
ordinary least square estimator with data modified by each estimated  , this study tested 
heteroscedasticity by employing the Breusch-Pagan test. Because the null hypothesis 
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(homoscedastic residual) of the Breusch-Pagan test was not rejected at the significance level of 
0.05, it was concluded that no heteroscedastic residuals are present in either of the QBC 
equations.  
 
Table 1.2. Estimation results for the quadratic Box-Cox functional form with the reference 
production value of 1.80 Met in MP 
 
 
Dependent variable: Milk protein content responses (g/100g) 
No. of Observation = 48, LR chi2(2) = 43.17, P > chi2 = 0 
 Estimate Standard error z-value P > z 
  0.3451 0.05 6.82 0.00 
Test H0 Restricted LR statistic P-value  
 log likelihood chi2 Prob > chi2  
  = -1 -413.6801 1038.67 0.00  
  =  0 57.3194 96.67 0.00  
  =  1 71.8203 67.67 0.00  
     
 
Dependent variable: Transformed milk protein content responses (g/100g) 
No. of Observation = 48,  P > F = 0.00, R
2
  = 0.59, Adj. R
2
  = 0.58 
 Estimate Standard error t-value P > t 
0  -9.0356 1.41 -6.43 0.00 
1  14.8872 3.23 4.61 0.00 
2  -7.2902 1.80 -4.06 0.00 
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Table 1.3. Estimation results for the quadratic Box-Cox functional form with the reference 
production value of 1.90 Met in MP 
 
In this study, the RPMet price is assumed to be $0.0141 per gram
2
, the TIAMet of an 
RPMet supplement is assumed to be 65.6%
3
, and the milk protein price is assumed to be $0.0046 
                                                 
2
 This price was arrived at by taking the base price of a commercially available RPMet supplement which contains 
85% of RPMet, sold to feed companies $0.012 per gram of RPMet and adjusting for profit after being added to feed 
and resold to farmers. 
  
Dependent variable: Milk protein content responses (g/100g) 
No. of Observation = 40, LR chi2(2) = 34.78, P > chi2 = 0 
 Estimate Standard error z-value P > z 
  0.4129 0.06 6.46 0.00 
Test H0 Restricted LR statistic P-value  
 log likelihood chi2 P > chi2  
  = -1 -332.3985 850.90 0.00  
  =  0 53.6245 78.85 0.00  
  =  1 70.1678 45.77 0.00  
     
  
Dependent variable: Transformed milk protein content responses (g/100g) 
No. of Observation = 40,  P > F = 0.00, R
2
  = 0.58, Adj. R
2
  = 0.56 
 Estimate Standard error t-value P > t 
0  -8.9451 1.55 -5.79 0.00 
1  14.0465 3.29 4.28 0.00 
2  -6.5771 1.71 -3.85 0.00 
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per gram, which was the average producer price for milk protein in 2006. Based on these 
assumptions, the estimated output elasticity and additional profit at various levels of the 
percentage of Met in MP are reported in Figures 1.2 and 1.3. These estimation results indicate 
that the optimal level of Met in MP for maximizing milk protein production is 2.40 percent and 
2.42%
4
, where the RPV is 1.80 and 1.90%, respectively. These optimal levels are almost 
identical to the recommended level of Met in MP of 2.40% in the NRC (2001). According to 
Equation (1.5), the amounts of RPMet required to increase the percentage of Met in MP from 
each RPV to the 2.40 and 2.42% are 21.6 and 18.5 g/d, respectively. On the other hand, the 
optimal level of Met in MP for maximizing profit is 2.32 and 2.34%, respectively. Again, 
according to Equation (1.5), the amounts of RPMet required to increase the percentage of Met in 
MP from each RPV to the 2.32 and 2.34% are 18.7 and 15.6 g/d, respectively. In each case, the 
additional daily profit per cow is estimated to be $0.38 and $0.29. These additional profit 
estimates are $0.02 higher than the additional profit estimates for maximizing milk protein 
production. Over a 300 day lactation period this is $6.00 per cow; with a herd of 1,000 cows this 
                                                                                                                                                             
3
 This is the TIAMet of the same commercial RPMet supplement whose price was assumed to be $0.0141 per gram 
in this study. 
4
 The optimal percentage of Met in MP for maximizing milk protein production is the point where the output 
elasticity equals zero and begins to be negative. 
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amounts to $6,000 cost savings per year using economic optimal rather than output maximum 
use of Met in MP. 
 
 
Figure 1.2. The estimated output elasticity and additional profit at various levels of the 
percentage of Met in MP where the reference production value of 1.80 Met in MP 
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Figure 1.3. The estimated output elasticity and additional profit at various levels of the 
percentage of Met in MP where the reference production value of 1.90 Met in MP 
 
If any initial assumptions on the milk protein price, the RPMet price or the TIAMet of an 
RPMet supplement are changed, the new optimal levels of Met in MP for maximizing milk 
protein production and profit, and the associated amounts of RPMet required to each optimal 
levels of Met in MP, can be computed by inserting the new assumptions into the profit analysis 
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formula provided in this study. This is because these initial assumptions do not affect the 
estimated parameters of the QBC in this study. For example, if we change the milk protein price 
of $0.0046 per gram in 2006 to $0.0037 per gram in 2000
5
, the optimal level of Met in MP for 
maximizing milk protein production and the amounts of RPMet required to increase the 
percentage of Met in MP from each RPV to the optimal level of Met in MP for maximizing milk 
protein production will not be changed. This is because the milk protein price only affects the 
additional revenue formula (Equation 1.6) without affecting the estimated parameters of the 
QBC in this study. Thus, the optimal level of Met in MP for maximizing profit is changed to 
2.30 and 2.32%, where the RPV is 1.80 and 1.90%, respectively. In this case, the amounts of 
RPMet required to increase the percentage of Met in MP from each RPV to the 2.30 and 2.32% 
are 18.0 and 14.9 g/d, respectively. In each case, the additional daily profit per cow is estimated 
to be $0.26 and $0.19. These additional profit estimates are $0.03 and $0.02 higher than the 
additional profit estimates for maximizing milk protein production. Similarly, if we change the 
milk protein price of $0.0046 per gram in 2006 to $0.0057 per gram in 2004
6
, the optimal level 
of Met in MP for maximizing profit is changed to 2.33 and 2.36%, respectively. The amounts of 
RPMet required to increase the percentage of Met in MP from each RPV to the 2.33 and 2.36% 
                                                 
5
 $0.0037 per gram was the lowest average producer price for milk protein over the last seven years. 
6
 $0.0057 per gram was the highest average producer price for milk protein over the last seven years. 
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are 19.1 and 16.4 g/d, respectively. In each case, the additional daily profit per cow is estimated 
to be $0.54 and $0.42. These additional profit estimates are $0.02 higher than the additional 
profit estimates for maximizing milk protein production. 
 Although additional profit per cow is always higher for maximizing profit than the 
additional profit per cow for maximizing milk production, the computed optimal levels of Met in 
MP for both maximizing protein production and maximizing profit are similar given the prices 
used for Met in MP and milk protein. Other prices will change the optimal profit input quantity 
which may differ more significantly from the input quantity to maximize milk protein output. 
Therefore, in targeting the percentage of Met in MP and the amounts of RPMet application, 
farmers should focus on maximizing profit and not maximizing milk protein production.  
 
Conclusion 
This study examines the profitability of rumen-protected methionine (RPMet) supplement on 
milk protein production. The impact of Met in metabolizable protein (MP) on milk protein 
production is first estimated from empirical data using a quadratic Box-Cox functional form. 
Then the additional daily profit per cow by adding various amounts of RPMet supplement to the 
diet of lactating cows is analyzed and reported using relevant input and output prices. The 
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optimal amount of RPMet to maximize daily profit per cow is compared to the RPMet required 
to maximize milk protein production. These optimal quantities are very similar given current 
prices for RPMet and milk protein, but additional profit estimates for maximizing daily profit per 
cow are $0.02 higher than the additional profit estimates for maximizing milk protein production 
given National Research Council reference production values of 1.80 and 1.90%. 
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CHAPTER 2 
COMPARTMENT MODEL FOR CONTROLLING INFECTIOUS LIVESTOCK DISEASE: 
COST EFFECTIVE CONTROL STRATEGIES FOR JOHNE'S DISEASE IN DAIRY HERDS 
 
Abstract 
An animal compartment framework is used to develop a conceptual model which incorporates 
the complexity inherent in disease-specific epidemiology in livestock. This conceptual model is 
empirically implemented with a discrete optimal control model to evaluate the economic and 
epidemiological consequences of various control strategies for Mycobacterium avium subspecies 
paratuberculosis (MAP), the pathogen causing Johne's disease (JD), in dairy herds. The empirical 
results indicate that control of MAP will significantly improve profitability for dairy producers 
with a JD-affected herd. The empirical application will aid in developing a comprehensive and 
effective JD control program and the result will help dairy producers understand the economic 
benefits of controlling MAP by either hygiene management or testing and slaughtering test-
positive animals. 
 
Introduction  
Infectious diseases in livestock play a critical role in determining profitability of individual farms 
and maintaining the sustainability of livestock industries. Some of these diseases are also linked 
to human diseases (Bender and Shulman, 2004, Groenendaal and Zagmutt, 2008, LeBlanc et al., 
2006). This potential threat of infectious animal diseases to human health, coupled with their 
high cost to the livestock industry, has increased public interest in developing successful and 
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cost-effective control programs that reduce the social and economic impact associated with 
livestock epidemics and to develop effective biosecurity programs.  
 Controlling infectious diseases in livestock is not straightforward, since the majority of 
these diseases have neither a fail-safe method of prevention nor a cure. In such cases, the success 
of infectious disease control in livestock becomes dependent on the producers’ willingness to 
initiate a control program and the effectiveness of these controls in reducing transmission of the 
disease. Consequently, successful control programs need to be determined based on joint 
consideration of the economic gain for livestock producers and the effects of control strategies 
on the infection dynamics of the disease. This implies that control strategies in such programs 
should be cost-effective in order to provide an economic incentive to livestock producers to 
adopt.  
 Prior literature on infectious livestock disease controls, however, has largely focused on 
either the reduction of farm-level economic losses while disregarding the infection dynamics of 
the disease (Chi et al., 2002b, Gramig et al., 2010, Mclnerney, 1996) or else on the eradication of 
the disease while the economic costs and benefits of disease control are either ignored or 
computed only for the predetermined control strategies satisfying the eradication conditions 
(Diekmann et al., 1990, Haydon et al., 1997, Matthews et al., 2006). Recently, the dynamic 
optimization approach with a simple susceptible-infected (SI) mathematical model has been 
increasingly applied to infectious wildlife disease control because it allows simultaneous 
evaluation of the economic and epidemiological tradeoffs associated with disease control 
(Fenichel and Horan, 2007, Fenichel et al., 2010, Horan and Wolf, 2005, Horan et al., 2008). 
However, none of these studies applied this approach to infectious disease control in livestock 
given the consideration of disease control characteristics in livestock. 
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 Wildlife disease control can be characterized as nonselective control since identifying 
infected wildlife prior to harvest is almost impossible and control options are basically limited to 
nonselective harvesting. In such a case, the epidemiological aspects of infectious diseases can be 
captured in a simple model, as the infection status is minimally important in nonselective disease 
control. In contrast, the health status of livestock can be largely controlled and monitored by 
producers. As a consequence, control strategies can be selectively applied to animals in different 
groups according to their production and health status. Therefore, a comprehensive disease-
specific epidemiological model is often required in livestock disease control.  
 The objectives of this study are twofold:  first, to develop a conceptual framework for 
evaluating the economics of an infectious disease control which can incorporate the complexity 
inherent in disease-specific epidemiology in livestock, and second, to evaluate the economic and 
epidemiological consequences of various control strategies for Mycobacterium avium subspecies 
paratuberculosis (MAP), the pathogen causing Johne’s disease (JD), which is a particularly 
serious infectious disease of dairy cattle due to its high prevalence and economic impact on the 
dairy industry (Tiwari et al., 2009, USDA NAHMS 2008, Wilson et al., 2010). 
Approximately 32% (Tiwari et al., 2009) and 68% (USDA NAHMS 2008) of dairy herds 
had at least one MAP-infected cow in Canada and the U.S., respectively. Given this high MAP 
prevalence, JD can have a devastating impact on the dairy industry; the annual cost per JD-
infected cow has been estimated to be as high as CD$2472 (Chi et al., 2002a) in Canada and 
US$1094 (Ott et al., 1999) in the U.S.. This high economic cost of JD prompted the creation of a 
national voluntary control program in Canada (2005) and the U.S. (2002), but relatively few 
producers have participated given the lack of solid information and evidence that these programs 
will economically benefit producers.  
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A limited number of simulation and field studies have attempted to estimate the 
economic benefits of controlling MAP infections and JD (Dorshorst et al., 2006, Groenendaal et 
al., 2002, Ott et al., 1999, Pillars et al., 2009). However, these studies did not take into account 
either the differences in the characteristics of various methods within a control strategy or their 
effects on the level of knowledge available to the producers in their decision making process. 
Moreover, given the nature of simulation and field studies, the results of most of these studies 
were limited to a predetermined set of control strategies.  
Our empirical control model for the causal pathogen of JD, MAP, incorporates both the 
disease-specific epidemiology in dairy cattle and the effect of the various possible controls on the 
epidemiological process, incorporating the dairy producers' decision making process. The model 
allows the level of controls, such as optimal culling (harvesting) levels, to be endogenously 
determined, rather than predetermined as a scalar. The empirical results will help dairy producers 
understand the economic benefits of controlling MAP, resulting in reduction of the prevalence 
and economic costs of JD, by providing answers to producers’ main questions, namely whether 
MAP control will improve their profitability and which control measures generate the most 
economic benefits with consideration of the economic impact of JD.  
 
Materials and methods  
Economic model for infectious animal disease control 
 Animals within a herd or region can be grouped into different compartment iI={1,…,I} 
according to their characteristics such as production- and infection-status. Let x(t)={x1(t),...,xI(t)} 
be the set of xi(t), iI={1,…,I}, representing the number of animals in compartment i at time t. 
y={y1,...,yN} is the set of control strategies yn, nN={1,…,N}. u={u1,...,uM} is the set of control 
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options um, mM={1,…,M= 






N
k k
N
1
}, that is a combination of control strategies such as 
improved hygiene management together with culling infected animals. Also, wi,j(x(t),um) is the 
transition rate
7
 from compartment i to j and can be interpreted as the net growth rate when i=j. 
Finally, Vi is the set of adjacent compartments of compartment i, which implies that animals in 
compartments in set Vi are moved into or out of compartment i in the next time period t+1 due to 
aging, production stage change, or disease progress. Then, the state dynamics of animals in 
compartment i can be represented by  
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   
  (2.1) 
 The first term in the right hand side (RHS) of Equation (2.1) represents the changes in the 
number of animals in compartment i due to net growth. The second term in the RHS of Equation 
(2.1) represents the number of animals moved into compartment i from adjacent compartments 
kVi. The third term in the RHS of Equation (2.1) represents the number of animals moved to 
adjacent compartments jVi from compartment i. Compartments k and j can be identical to or 
different from each other depending upon the epidemiological process of a disease. When 
compartment i represents offspring from parent animals in compartment s, Equation (2.1) can be 
augmented with the term 
 iZs
smis txutxb )()),((,  where bs,i(x(t),um) is the birth rate of parent 
animals in compartment s that produce offspring in compartment i and Zi is the set of 
compartments for parent animals. 
                                                 
7
 This is the general form of the transition rate between compartments since the rate is generally affected by control 
strategies in a control option and can be also affected by the number of animals in different compartments when this 
rate is frequency- or density-dependent. 
 34 
 
 Given a discount factor (0,1)8, net benefit function  terminal function F, and control 
option um, a livestock producer or a social planner's economic objective is 
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( ( ), ) ( ( ))
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i i
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t T
m
x t
t
Max N x t u F x T 



  (2.2) 
subject to a total of I equations of motion having the form of Equation (2.1), initial number of 
animal stock x(1)={x1(1),...,xI(1)}, and other possible feasibility conditions such as capacity 
constraints that define and limit the domain of x(t). Since this is a finite-dimensional 
optimization model, a solution exists provided that objective function and equations of motion 
are continuous and that x(t) is a compact set.  
In disease control, the majority of control strategies are generally treated as parameters 
(determined outside of the optimization process), as in Equation (2.2), since such strategies (e.g. 
a certain level of hygiene management) are assumed to be determined at the initial period of 
control and consistently performed by producers. However, some control strategies can be 
variables (determined in the optimization process). For example, culling rates of cows associated 
with the control strategy involving diagnostic testing and slaughter of test-positive cows can vary 
depending on the number of cows in a herd and the capacity constraints of farm. In this case, the 
control strategy will also be a choice variable and affect the number of animals in associated 
compartments, such as compartments for cows and future newborn animals.  
 When set Vi in Equation (2.1) is identical to set I, the above optimization model becomes 
the prototype bioeconomic model used in prior economic studies on wildlife disease control and 
analytic or qualitative solutions are generally obtained by using either dynamic programming- or 
maximal principle-techniques (Fenichel and Horan, 2007, Fenichel et al., 2010, Horan and Wolf, 
                                                 
8
  can be represented by r where r is a discount rate.  
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2005, Horan et al., 2008). Otherwise, Vi≠I implies that animals in compartments belonging to Vi 
are linked to other compartments not belonging to Vi via different time lags due to the complex 
epidemiological progress of a disease, such as multi-stage infection. This complexity often 
precludes obtaining analytic or qualitative solutions and the optimization model may only be 
solved by numerical computation, which is the case in the present study, which has 14 different 
animal compartments. 
 
Epidemiology of Johne's disease and control strategies 
 JD is a chronic, infectious, untreatable disease of ruminants, caused by the pathogen 
MAP. Animal infection states of MAP in a dairy herd are classified as: susceptible, resistant, 
transient, latent, low-shedding, and high-shedding (Lu et al., 2010, Mitchell et al., 2008). 
Animals in the susceptible and resistant states are non-infected (free of MAP infection). Animals 
in the transient state are infected animals that shed MAP transiently at a low level and are not 
generally tested with currently available MAP diagnostic tests due to their young age. Animals in 
the latent state are infected animals that shed no MAP. Animals in the low-shedding state shed 
low levels of MAP, ≤ 30 cfu/g, while animals in the high-shedding state shed high levels of 
MAP, >30 cfu/g (Whitlock et al., 2000).  
 Animals are typically susceptible to infection up to the age of 12 months and then 
become resistant (Collins and Morgan, 1991). Susceptible animals can be infected following 
contact with MAP in fecal shedding from infected animals (Whitlock et al., 2005), in colostrum 
and milk of infected adults (Sweeney et al., 1992a), and in contaminated environments (USDA 
NAHMS 1997). Newly infected animals enter the transient state, which often develops within a 
few days of infection and continues up to 6 months (Rankin, 1961). Some newborn animals from 
 36 
 
infected dams directly enter this state at the time of birth via in-utero infection (Sweeney et al., 
1992b). Given the duration of susceptible and transient states, animals in this state are typically 
younger than 18 months old. The latent state generally occurs following the transient state and 
continues for a long duration, but animals older than 24 months in this state begin to enter the 
low-shedding state and then the high-shedding state as the disease progresses.  
Symptoms of JD are most commonly seen in adults and include reduced milk production, 
body weight losses, and increased mortality (USDA NAHMS 1997, Groenendaal et al., 2002, 
Nielsen and Toft, 2008, NRC, 2003, Smith et al., 2009). The transient and latent states are 
considered to be the incubation stage of JD since they are generally non-detectable with no 
symptoms. The low-shedding state can be considered to be the subclinical stage of JD as its 
symptoms begin to appear, that is, milk production and body weight begins to decrease. The 
high-shedding state can be considered to be the clinical stage of JD as considerable reduction in 
milk production and body weight is often present in animals in the high-shedding state. Animals 
in the high shedding state may develop diarrhea and have a higher mortality rate.  
 Typical MAP and JD control strategies include hygiene management and test-and-cull. 
Hygiene management reduces infection transmission rate in animals in the susceptible state by 
decreasing exposure to MAP. Test-and-cull is the diagnostic testing and slaughter of test-positive 
animals. A fecal culture (FC) test and an enzyme-linked immunosorbent assay (ELISA) test are 
the two main tests for detecting MAP infection (USDA NAHMS 2008), generally applied to 
adult cows. Test-and-cull reduces both MAP infection prevalence and JD-affected animals by 
removing infectious animals, but the efficacy of test-and-cull significantly varies depending on 
the test frequency and the characteristics of MAP diagnostics such as the test sensitivity, test 
specificity, and identification ability.  
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 Test specificity is the probability of classifying uninfected animals as test-negative. Since 
currently available MAP tests generally fail to detect infected animals shedding no MAP, 
animals in the test-negative classification are assumed to be a combination of animals free of 
MAP infection and infected animals shedding no MAP, which includes infected animals in the 
latent state of MAP infection. Therefore, a test with specificity less than 1 would generate false 
positive test results for not only animals free of MAP infection, but also infected animals 
shedding no MAP. On the other hand, test sensitivity is the probability of classifying infected, 
shedding animals as test-positive. In contrast to the test-negative classification, animals in the 
test-positive classification are assumed to be infected animals shedding MAP, which include 
animals in the low- and high-shedding states of MAP infection. Therefore, a test with sensitivity 
less than 1 would generate false negative test results for low- and high-shedding animals (Lu et 
al., 2008, Smith et al., 2009, Whitlock et al., 2000). Identification ability is the test’s ability to 
detect specific MAP infection states of animals in the test-positive classification. A test, such as 
FC, that has identification ability allows producers to apply different culling rates for animals in 
low- and high-shedding states. With tests that do not have identification ability (such as an 
ELISA test), producers can only apply a single culling rate for test positive animals since they 
cannot separately identify whether these animals are low- or high-shedding.  
 
Empirical model  
 In this study, animals are grouped into 14 discrete and disjoint compartments (Table 2.1), 
I={1,…,14}, that are constructed based on the epidemiology of MAP infection described in the 
previous section. Each compartment iI represents animals in different infection states and ages 
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with 6-month time steps. Infection states are related to the level of infectiousness
9
, productivity
10
, 
and mortality
11
. Age is related to susceptibility to infection, duration of infection states, and 
production stage.  
 
Table 2.1. Definition of animal compartments 
Compartment Description 
1 Compartment for calves 0-6 months in the susceptible state 
2 Compartment for calves 0-6 months in the transient state 
3 Compartment for calves 6-12 months in the susceptible state 
4 Compartment for calves 6-12 months in the transient state 
5 Compartment for calves 6-12 months in the latent state 
6 Compartment for heifers 12-18 months in the resistant state 
7 Compartment for heifers 12-18 months in the transient state 
8 Compartment for heifers 12-18 months in the latent state 
9 Compartment for heifers 18-24 months in the resistant state 
10 Compartment for heifers 18-24 months in the latent state 
11 Compartment for cows in the resistant state 
12 Compartment for cows in the latent state 
13 Compartment for cows in the low-shedding state 
14 Compartment for cows in the high-shedding state 
Note: The terms calves, heifers, and cows are defined as animals younger than 12 months, 
between 12 and 24 months, and older than 24 months that produce offspring and milk, 
respectively.  
 
                                                 
9
 Infected animals shedding higher levels of MAP for longer periods infect more susceptible animals either directly 
or indirectly through contaminating their environments. Thus, horizontal infectiousness of infected animals follows 
this order: high-shedding, low-shedding, transient. 
10
 Milk production and body weight begins to decrease in animals in the low-shedding state and they decrease 
considerably in animals in the high-shedding state. 
11
 Only animals in the high-shedding state have a high mortality rate due to JD. 
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 The equations of motion for animals in compartments 1 and 2 take the form of Equation 
(2.1) with the additional term 
 iZs
smis txutxb )()),((,  where bs,i(x(t),um) is the birth rate of newborn 
animals in compartment i from parent animals in compartment s and Z1={11, 12, 13, 14} and 
Z2={12, 13, 14} are the set of compartments for parent animals that produce offspring in 
compartments 1 and 2, respectively, while the equations of motion for animals in other 
compartments take the form of Equation (2.1) without the additional term. All rates associated 
with the equations of motion for animals in each compartment are presented in Tables 2.2-2.3.  
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Table 2.2. Birth rate for female calves and net growth rate of animals (6 month basis) 
Rate Description Value 
b11,1 Birth rate for susceptible female calves from resistant cows 0.215 
b12,1 Birth rate for susceptible female calves from latent cows   
b12,2 Birth rate for transient female calves from latent cows 
 
b13,1 Birth rate for susceptible female calves from low shedders   
b13,2 Birth rate for transient female calves from low shedders 
 
b14,1 Birth rate for susceptible female calves from high shedders  
b14,2 Birth rate for transient female calves from high shedders 
 
wi,i Natural death rate of calves (animals in compartments i=1,2,3,4,5)
   
 
Natural death rate of heifers (animals in compartments i=6,7,8,9,10)
 

 
w11,11 Removal rate of resistant cows
 
Varies 
w12,12 Removal rate of transient cows

Varies 
w13,13 Removal rate of low-shedding cows  Varies 
w14,14 Removal rate of high-shedding cows

Varies 
Sources: Birth rates are obtained from USDA NAHMS (2007) and Lu et al (2010). Natural death 
rates are obtained from USDA NAHMS (2007). 
Note: In our age-structured compartment model, natural growth of herd size is allowed only 
through birth of newborn calves. Hence, the net growth rate of calves and heifers becomes the 
natural death rate of these animals and that of cows becomes the removal rate, which is the sum 
of natural death rate, general culling rate due to low production or diseases other than Johne's 
disease, and additional culling rate due to test-and-cull. General and additional culling rates 
associated with removal rate of cows are obtained by solving the control model empirically.  
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Table 2.3. Transition rate between adjacent compartments (6 month basis) 
Rate Description Value 
w1,3 Susceptible calves 0-6 months → Susceptible calves 6-12 months Varies 
w1,4 Susceptible calves 0-6 months → Transient calves 6-12 months Varies 
w2,5 Transient calves 0-6 months → Latent calves 6-12 months 
 
w3,6 Susceptible calves 6-12 months → Resistant heifers 12-18 months Varies 
w3,7 Susceptible calves 6-12 months → Transient  heifers12-18 months Varies 
w4,8 Transient 6-12 months → Latent 12-18 months 
 
w5,8 Latent 6-12 months → Latent 12-18 months 
 
w6,9 Resistant heifers 12-18 months → Resistant heifers 18-24 months 
 
w7,10 Transient heifers 12-18 months → Latent heifers 18-24 months 
 
w8,10 Latent heifers 12-18 months → Latent heifers 18-24 months 
 
w9,11 Resistant heifers 18-24 months → Resistant cows 
 
w10,12 Latent heifers 18-24 months → Latent cows 
 
w12,13 Latent cows → Low-shedding cows 
 
w13,14 Low-shedding cows → High-shedding cows 
 
Sources: All rates are obtained from USDA NAHMS (2007) and previous studies on 
Mycobacterium avium subspecies paratuberculosis and Johne’s disease in dairy herds. 
Detailed information on these rates is explained in the empirical model section. 
Note: Movement of animals from one compartment to another is due to aging, infection, or 
infection progress. Transition rates due to aging are w1,3, w3,6, w5,8, w6,9, w8,10, w9,11, and  w10,12. 
Transition rates due to infection are w1,4 and w3,7. Transition rates due to infection progress are 
w2,5, w4,8, w12,13, and w13,14. 
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 The relationship between compartments is illustrated in Figure 2.1, where xi represents 
the number of animals in compartment iI (Table 2.1), bs,i is the birth rate of parent animals in 
compartment s that produce offspring in compartment i (Table 2.2), wi,j is the transition rate from 
compartment i to adjacent compartment j (Table 2.3). This flow diagram of animal 
compartments is constructed based on our previous mathematical model for MAP infection in 
dairy herds (Lu et al., 2010, Mitchell et al., 2008). Detailed information on the animal movement 
between compartments is described in these  
 
  
Figure 2.1. The flow diagram of animal compartments and infection with MAP 
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 In this study, vertical infections from parent animals to their offspring are captured in the 
birth rates for transient calves. These vertical infections are set at12=0.15,13=0.15, and 
=0.17 representing portion infected at birth given infected dams in compartments 12 (latent 
cows), 13 (low-shedding cows), and 14 (high-shedding cows) as in a prior modeling study (Lu et 
al., 2010). Given these proportional parameters, the birth rates for transient female calves from 
infected dams (b b, and bin Table 2.2) are obtained from bb bb13, 
and bb, while the birth rates for susceptible female calves from those dams (b b 
and b in Table 2.2) are obtained from bb,
 
bb
 and bb, 
where b=0.215 represents the average birth rate for female calves on a 6-month basis (USDA 
NAHMS 2007). 
 Horizontal MAP infection is generally determined by the number of infected animals that 
shed MAP in transient (x2, x4, and x7), low-shedding (x13), or high-shedding states (x14), since 
manure containing MAP is the main source of infection for susceptible animals either directly or 
indirectly through contaminated environments. In a prior modeling study (Lu et al., 2008), this 
horizontal infection is captured in the force of infection (t): 
 2 4 7 13 13 14 14( ) [ { ( ) ( ) ( )} ( ) ( )] / ( )Trt x t x t x t x t x t N t         (2.3) 
where N(t) is the total number of animals on a farm at time t and Tr=1, 13=2,and 14=10 are 
transmission rates between susceptible animals and infected animals in transient (compartments 
2,4, and 7), low-shedding (compartment 13), and high-shedding states (compartment 14), 
respectively.  
 The JD control strategies considered in this study include two different levels of hygiene 
management and four different test-and-cull methods, summarized in Table 2.4. These control 
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strategies reduce the horizontal infection transmission rate in animals in the susceptible state by 
decreasing the exposure of susceptible animals to infected manure. Either improved or advanced 
hygiene management reduces the force of infection (t) in Equation (2.3). Given the force of 
infection, together with the impact of hygiene management, the transmission rates of animals 
from the susceptible state to the transient state (w1,4(t) and w3,7(t) in Table 2.3) can be represented 
by w1,3(t)=w1,4(t)=t, where  represents the effect of hygiene management on reduction 
of the force of infection with the assumption of  for improved hygiene and  for 
advanced hygiene. These estimates of are based on prior studies (Dorshorst et al., 2006, 
Groenendaal et al., 2002). Susceptible animals remaining after infection with (t) and natural 
death move to other susceptible or resistant compartments due to aging. These movements are 
captured in transition rates w1,3(t) and w3,6(t) in Table 2.3, which are obtained from 
w1,3(t)=tw1,1 and w3,6(t)=tw3,3, where both w1,1 and w3,3 are 0.046,  
which is the natural death rates of calves (USDA NAHMS 2007). 
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Table 2.4. Control strategies for Johne's disease 
Control strategy Description 
Improved hygiene
 
Improved hygiene includes harvesting colostrum from cows with 
cleaned and sanitized udders and preventing contact of calves with 
adult cow manure 
Advanced hygiene
 
Advanced hygiene includes feeding calves with only milk replacer 
or pasteurized milk, preventing contamination of calf feedstuffs, 
water, or bedding by effluent from the adult herd as well as 
hygiene practices included in improved hygiene
 
Test-and-cull using 
annual FC test 
Testing  cows once a year (half at midyear and the other half at the 
end of year) using fecal culture test and culling test-positive cows 
Test-and-cull using 
annual ELISA test 
Testing cows once a year using enzyme-linked immunosorbent 
assay test and culling test-positive cows 
Test-and-cull using 
biannual FC test 
Testing cows twice a year (once at midyear and once at the end of 
year) using fecal culture test and culling test-positive cows 
Test-and-cull using 
biannual ELISA test 
Testing cows twice a year using enzyme-linked immunosorbent 
assay test and culling test-positive cows 
Note: Both improved hygiene and advanced hygiene include additional hygiene practices defined 
previously, as well as all hygiene practices assumed to be currently implemented by typical dairy 
farms. In particular, advanced hygiene is designed to provide a hygiene environment identical to 
off-farm calf rearing. The difference between improved hygiene and advanced hygiene is that 
while both are assumed to decrease infection transmission between susceptible and infectious 
animals, the latter is additionally assumed to decrease infection transmission between susceptible 
animals and surrounding environments contaminated mainly by manure containing 
Mycobacterium avium subspecies paratuberculosis. 
 46 
 
 Four different test-and-cull methods in Table 2.4 affect the removal rate of cows 
depending on test frequency and the characteristics of the test including specificity, identification 
ability, and sensitivity for low- and high-shedding cows
12
. In this study, cows are assumed to exit 
the herd in three different ways: a natural death, a general culling due to low production or 
diseases other than JD, or an additional culling due to test-and-cull for cows with a positive MAP 
test result. Given this assumption, the removal rate of cows (w11,11(t), w12,12(t), w13,13(t), w14,14(t) 
in Table 2.3) can be represented by: 
 
11,11( ) [ {1 (1 )} ( ) (1 ){ ( ) ( )}]c c L L H Hw t t t t                  (2.4) 
 
12,12( ) [ {1 (1 )} ( ) (1 ){ ( ) ( )}]c c L L H Hw t t t t                  (2.5) 
 
13,13( ) [ (1 ) ( ) ( )]c L c L Lw t t t          (2.6) 
 
14,14( ) [ (1 ) ( ) ( )]c H c H Hw t t t            (2.7) 
where c=0.126 represents the natural death rate (USDA NAHMS 2007). c represents the 
general culling due to low production or diseases other than JD. L represents the additional 
culling due to test-and-cull for the low-shedding cows with a positive MAP test result. H 
represents the additional culling due to test-and-cull for the high-shedding cows with a positive 
MAP test result. The parameter  represents test frequency, indicating either annually () 
or biannually
14
 (  represents specificity of a MAP test with  for an ELISA test and 
 for a FC test. L and H represent test sensitivity for low- and high-shedding cows, 
respectively, with L=0.3 and H=0.75 for an ELISA test and L=0.5 and H=0.9 for a FC test 
(Collins et al., 2006, Nielsen and Toft, 2008, Whitlock et al., 2000). L and H represent the 
                                                 
12
 Test specificity, identification ability, and test sensitivity are defined in the previous section. 
13
 An annual test is one in which all animals are tested once a year, half at midyear and the other half year-end. 
14
 A biannual test is one in which all animals are tested twice a year, once at midyear and once year-end. 
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proportion of cows with a positive test result that are erroneously identified as low- or high-
shedding cows due to imperfect identification ability of a diagnostic test
15
. A FC test has 
identification ability, but an ELISA test does not. In this study, the proportions L and H are 
assumed to be determined by the ratio of the test sensitivity for low- and high-shedding cows as 
L=L/(L+H) and H=H/(L+H), where L+H=1. 
 In Equations (2.4)(2.7), the proportion of resistant and latent cows with a positive test 
result is represented by ) and these positive test results are false positive due to imperfect 
test specificity (. On the other hand, the proportion of low- and high-shedding cows with a 
positive test result is represented by L and H, respectively, and these positive test results are 
true positive given the perfect test specificity associated with FC of low- and high-shedding cows. 
All cows in each compartment i={11,12,13,14} exit the herd at fixed rate c due to natural death. 
All cows in the high-shedding state also exit the herd at an additional rate  due to the 
clinical symptoms of JD (Whitlock et al., 2000). All cows with a positive test result can exit the 
herd by additional culling ratesLL+HHfor resistant and latent cows,L for low-shedding 
cows, and H for high-shedding cows, whereL=H for a test does not have identification 
ability
17
. Thus, ){LL+HH}, LL, and HH in Equation (2.4)(2.7) can be interpreted 
as the proportion of cows in each compartment that are removed from the herd because of test-
                                                 
15
 L and H equal zero for a FC test since this test has identification ability, while they are non-zero for an ELISA 
test since this test does not have perfect identification ability. 
16
 There will be no cows with a false-positive test result for a FC test since it is assumed to have perfect test 
specificity (), while some false-positive test results are observed for an ELISA test due to its imperfect test 
specificity ( 
17
 A test, such as FC, that has identification ability allows producers to apply different culling rates for cows in low- 
and high-shedding states. Otherwise, producers can only apply a single culling rate for test positive cows since they 
cannot separately identify whether these cows are low- or high-shedding. This is the case for an ELISA test. 
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positive status. Remaining cows, which are untested or have a negative test result, can exit the 
herd by a general culling rate c due to low production or diseases other than JD. 
 In general, a dairy farm has an upper limit on the number of cows due to limited cow 
housing and management capacity and also a minimum number of cows necessary to generate 
cash flow for living and fixed expenses. These constraint factors can be imposed in the model by 
the following capacity constraint: 
 mincow cow maxow( )N N t N   (2.8) 
where Ncow(t) denotes the total number of cows at time t, Nmincow denotes the minimum 
number of cows, and Nmaxcow denotes the maximum number of cows on a farm. 
Given the epidemiological
18
 and capacity constraints, the producer’s objective is to 
maximize the expected net present value (NPV) from the sales of milk and cull cows for 
slaughter by deciding upon a combination of the control strategies in Table 2.5. Hygiene-
associated control strategies are discrete and treated as parameters (determined outside of the 
optimization process) in the model since these are assumed to be determined at the initial period 
of control and we assume that producers do not alter their initial choices of hygiene management 
unless the disease is eliminated. On the other hand, culling-associated control strategies are 
continuous variables (determined in the optimization process) in the model and determine the 
number of cows in each compartment. In addition, this study assumed that the farm would no 
longer implement any control strategies when the disease was eliminated.  
 
                                                 
18
 Epidemiological constraints are the equations of motion for age-structured compartments describing the 
epidemiological process of Johne's disease. 
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Table 2.5. Control strategy combinations 
Notation Definition 
u1 Improved hygiene 
u2 Advanced hygiene  
u3 Test-and-cull using annual FC test 
u4 Test-and-cull using annual ELISA test 
u5 Test-and-cull using biannual FC test 
u6 Test-and-cull using biannual ELISA test 
u7 Improved hygiene with test-and-cull using annual FC test 
u8 Improved hygiene with test-and-cull using annual ELISA test 
u9 Improved hygiene with test-and-cull using biannual FC test 
u10 Improved hygiene with test-and-cull using biannual ELISA test 
u11 Advanced hygiene with test-and-cull using annual FC test 
u12 Advanced hygiene with test-and-cull using annual ELISA test 
u13 Advanced hygiene with test-and-cull using biannual FC test 
u14 Advanced hygiene with test-and-cull using biannual ELISA test 
 
 The expected NPV of a producer’s net cash flow from the sales of milk and cull cows for 
slaughter is specified as: 
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This Equation (2.9) includes the expected revenue from milk sales, the expected revenues from 
cull cows sold for slaughter, and the operating cost of raising animals and the cost associated 
with a combination of control strategies in Table 2.5. The entire herd is liquidated at the 
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beginning of the terminal year. For the sake of model brevity, all remaining cows in the terminal 
years are sold at the price of healthy cows. This is a reasonable approach given that, with 
controls, effectively no cows show symptoms of JD
19
 in the final year of the 50-year simulation 
period. Young stock is all sold at the price of one year old animals, the average age of young 
stock. The variables and parameters in Equation (2.9) are presented in Table 2.6. 
 
                                                 
19
 Reduction in milk production and body weight. 
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Table 2.6. Definition of variables and parameters used in the net present value equation 
Rate Description Value
a 
Reference 
Ccalf Base operating cost of raising a calf 395.00 Karszes et al 2008 
Ccow Base operating cost of raising a cow 1231.46 USDA NASS 2003-2007 
Cheifer Base operating cost of raising a heifer 395.00 Karszes et al 2008 
Cmgt Extra cost associated with advanced hygiene  26.25 Dorshorst et al 2006 
 Extra cost associated with improved hygiene 15 Dorshorst et al 2006 
Ctest Cost of ELISA test per sample 5.00 Collins et al 2006 
 Cost of FC test per sample 19.00 Collins et al 2006 
H Suspected numbers of cows in clinical stage Varies Calculated 
L Suspected numbers of cows in subclinical stage Varies Calculated 
Ncalf Number of calves Varies Calculated 
Ncow Number of cows Varies Calculated 
Nheifer Number of heifers Varies Calculated 
Pcull Cull-cow price per pound 0.4788 USDA NASS 2003-2007 
Pmilk Milk price per pound 0.1539 USDA NASS 2003-2007 
Psale Sale price of a one year old animal  867
c
 Karszes et al 2008
 
Qcull Pounds (weight) of cull cow 1500 USDA NASS 2003-2007 
Qmilk Pounds of milk production per cow 9719.5 USDA NASS 2003-2007 
r Discount rate  0.02
 
Assumed 
T Total follow up time of a dairy farm 100 Assumed 
Z Suspected numbers of cows in non-clinical stage Varies Calculated 
c General culling rate for cows Varies Calculated 
H Extra culling rate for low-shedders Varies Calculated 
L Extra culling rate for high-shedders Varies Calculated 
 Test frequency  0.5 or 1 Assumedb 
H Production adjustment factor for high-shedders  0.1
 
Groenendaal et al 2002
d 
L Production adjustment factor for low-shedders 0.05
 
Groenendaal et al 2002
d 
H Cull-weight adjustment factor for high-shedders 0.1 Assumed 
L Cull-weight adjustment factor for low-shedders 0.05 Assumed 
a. Values are 6-month basis.  
b. represents annual testing and represents biannual testing. 
c. Sale price of a one year old animal is assumed to be identical to total cost of raising 
replacement heifer up to one year.  
d. Production reduction due to Johne's disease has been reported 5% to 20%. 
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 The differences in the characteristics of various testing options affect the level of 
knowledge available to the producers in their decision making process. In Equation (2.9), Z is 
suspected numbers of cows in the non-clinical stage (resistant and latent state), while L and H 
are suspected numbers of cows in the subclinical stage (low-shedding state) and the clinical stage 
(high-shedding state), respectively. Producers expect Z to have normal milk production and body 
weight, while they expect L and H to have lower milk production and body weight due to the 
disease. These production reductions due to JD are captured in the parameters L, H, L, and H 
in Equation (2.9) and presented in Table 2.6  
 Given imperfect specificity or sensitivity of currently available diagnostic tests, L and H 
represent producers' expectation on the number of low- and high-shedding cows in their herd and 
they are determined based on the number of cows with a positive-test result as shown in 
Equations (2.10) and (2.11).  
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Since a FC test has perfect identification ability and test specificity, cows with a positive-test 
result
20
 are either low-shedding (Lx13) or high-shedding (Hx14) in Equations (2.10) and (2.11). 
On the other hand, cows with a positive-test result21  based on an ELISA test, which has 
imperfect test specificity, are either resistant ()x11), latent ()x12), low-shedding 
                                                 
20
 The proportion of low- and high-shedding cows with a positive test result is represented by L and H in 
Equations (6) and (7), respectively. 
21
 The proportion of low- and high-shedding cows with a positive test result is represented by L and H in 
Equations (6) and (7), respectively. Similarly, a proportion of resistant and latent cows will have a positive test result 
given test specificity and this is expressed as ) in Equations (4) and (5).   
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(Lx13), or high-shedding (Hx14) in Equations (2.10) and (2.11). In addition, since an ELISA 
test doesn't have identification ability, a portion (L) of these cows is considered in low-shedding 
and the remaining portion (H) of these cows is considered in high-shedding
22
. The number of 
suspected cows (Z) in the non-clinical stage is the total number of cows (Ncow) minus the 
numbers of suspected low- and high-shedding cows (L and H, respectively). 
 cow( ) ( ) ( ) ( )Z t N t L t H t    (2.12) 
Since a mean true prevalence level of 10% MAP infection within a dairy herd is 
commonly assumed (Dorshorst et al., 2006, Van Schaik et al., 2003, Wells et al., 2002), three 
initial MAP infection levels (0%, 10%, and 20%)
23
 were considered for the baseline farm, in 
order to take into account the majority of dairy farm situations. The model described in this 
section was coded using the general algebraic modeling system (GAMS) software and 
empirically solved for a farm with these possible MAP infection levels. 
 
Results and discussion 
For a farm free of MAP (0% MAP infection level), the NPV is $374,305 for the 50-year 
simulation period. The NPV is estimated to be considerably lower at $161,938 and $98,830 
when the initial infection rate is 10% and 20%, respectively, in the absence of controls. This 
illustrates the potentially high cost of JD on dairy farms without control. The number of infected 
cows for a farm without MAP control in place increases continuously as reported in previous 
                                                 
22
 L and H represent the proportion of cows with a positive test result that are erroneously identified as low- or 
high-shedding cows due to imperfect identification ability of a diagnostic test, ηL+ηH=1. These are previously 
discussed with Equations (4) and (5). 
23
 An initial infection distribution for animal groups was simulated for a farm with an initial herd of 99 non-infected 
cows and 1 latently infected cow, and no control implemented. The initial conditions for the state variables for a 
farm with three different MAP infection levels were drawn from time-points in this simulation that matched the 
desired infection level. Each infection level represents a percentage of MAP infected cows per all cows in a herd. 
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studies (Groenendaal and Galligan, 2003, Groenendaal et al., 2002). These low NPV values 
would not be sustainable and implies that a farm would need to engage in some type of remedial 
action before JD becomes pervasive in the herd. Indeed, removing the lower cow number 
constraint eventually results in the sale of all cows, which would be expected with an epidemic 
infection rate.    
With MAP present, the results show that culling all test-positive animals over time is 
optimal for maximizing the NPV of a farm's net cash flow. The optimal rate of base line culling
24
 
varies depending up on the number of healthy and MAP-infected cows, but the steady-state rate 
is  (19.2% replacement rate) when there are no MAP-infected cows. This steady-state rate 
is close to the average cow removal rate of 23.6%, reported by USDA NAHMS (2007). A herd 
size of 100 cows, the upper cow constraint, is the steady-state herd size when there are no MAP-
infected cows or at the conclusion of a successful control program. The NPV and expected 
elimination
25
 period of MAP and of test-positive animals for various control scenarios are 
summarized in Table 2.7.  
                                                 
24
 The general culling rate c in Equations (2.4)-(2.7). 
25
 MAP is considered to be eliminated when its prevalence rate is less than 1%, while test-positive cows are 
considered to be eliminated when the total number is less than 0.5. 
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Table 2.7. Farm NPV and expected elimination period of the disease and of test-positive animals 
for a farm with a MAP-infected herd 
Control option
 
Infection 
level 
NPV 
Elimination of 
MAP
a 
Elimination of 
test-positive cows
a 
Test-and-cull Hygiene 
Annual 
FC test 
None 
10% $331,502
 
31 years 16 years 
20% $319,304 40 years 24.5 years 
Annual 
FC test 
Improved 
hygiene 
10% $345,603 6 years 4 years 
20% $336,873 7.5 years 5.5 years 
Annual 
FC test 
Advanced 
hygiene 
10% $337,611 5.5 years 4 years 
20% $329,091 6.5 years 5 years 
Biannual 
FC test
 None 
10% $332,975 12 years 9 years 
20% $320,201 15.5 years 12.5 years 
Biannual 
FC test 
Improved 
hygiene 
10% $341,857 5 years 4 years 
20% $333,404 6 years 5.5 years 
Biannual 
FC test 
Advanced 
hygiene 
10% $336,569 4.5 years 4 years 
20% $326,262 5.5 years 5 years 
Annual 
ELISA test
 None 
10% $327,942 Never Never 
20% $313,313 Never Never 
Annual 
ELISA test 
Improved 
hygiene 
10% $337,963 9 years Never 
20% $328,501 11 years Never 
Annual 
ELISA test
 
Advanced 
hygiene 
10% $329,376 7.5 years Never 
20% $321,258 8.5 years Never 
Biannual 
ELISA test
 None 
10% $307,066 Never Never 
20% $298,546 Never Never 
Biannual 
ELISA test 
Improved 
hygiene 
10% $334,697 7.5 years Never 
20% $322,893 9.5 years Never 
Biannual 
ELISA test 
Advanced 
hygiene 
10% $327,352 6.5 years Never 
20% $314,935 8 years Never 
None
 
Improved
 10% $336,182 11 years -
 
20% $319,040 14 years - 
None
 
Advanced
 10% $327,559 8.5 years
 
- 
20% $310,351 10.5 years - 
a. MAP is considered to be eliminated when its prevalence rate is less than 1%. Test-positive 
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cows are considered to be eliminated when total number of infected cows is less than 0.5. 
Note: For a farm free of MAP (0% MAP infection level), the NPV is $374,305, while the NPV at 
10% and 20% with no controls are 57% lower at $161,938 and 74% lower at $98,830 when the 
initial infection rate is 10% and 20%, respectively, in the absence of controls. 
  
 The most cost-effective control option is improved hygiene management and test-and-
cull using an annual FC test. This control option generates an NPV of $345,603 and $336,873, 
which are significantly higher compared to a farm without control given the initial infection rate 
of 10% and 20%, respectively. Implementing this option eliminates the MAP from the herd 
within 8 years for both MAP prevalence levels. Figure 2.2 shows the annual net cash flow 
associated with this control option together with no control for comparison. Although MAP 
control generates additional cost until the infection is eliminated, the overall benefit of control is 
much higher than no control with both 10% and 20% prevalence. This Figure also illustrates one 
reason farmers may not start a control strategy; the control costs are much higher initially than 
the lost income from JD. Reluctance to engage in MAP control is especially strong when farms 
would clearly experience the definite control cost but with actual losses from JD being nebulous. 
Therefore, it is important to inform producers that although initiating a control program  results 
in a higher net cash flow compared to no control, they will experience a negative net cash flow at 
the beginning of initiating a control program. The control program will result in a higher NPV 
than no control and provide an economic rationale to producers for initiating a control program. 
 57 
 
 
 
Figure 2.2. Annual net cash flows over first 15 years with no controls and with controls of 
improve hygiene and culling using an annual fecal test 
Note: The sudden increases in net cash flow are caused by discontinuation of controls. 
 
 For producers whose goal is to control MAP by implementing only a single control 
strategy, improved hygiene management generates the overall highest NPV among all single 
control strategies available for a farm with JD present. Test-and-cull using a FC test is an 
effective control strategy since it eliminates MAP, but this control strategy requires a 
considerably longer elimination period compared to that for a farm implementing improved 
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hygiene management. On the other hand, test-and-cull using an ELISA test is an ineffective 
control strategy. This control strategy decreases the MAP infection prevalence, but fails to 
eliminate MAP over the extended planning duration of a dairy farm.  
 Due to imperfect test sensitivity or specificity, it is difficult to identify whether MAP has 
been eliminated or not when using a MAP test only, especially an ELISA test. However, 
elimination of MAP can be ascertained in the model by observing the computed net cash flow
26
. 
When the net cash flow associated with a control option reaches a steady state net cash flow in 
our model, which equals $8,255 minus the cost of implementing the control option, it implies 
that MAP has been eliminated. This is because a net cash flow of $8,255 is identical to the net 
cash flow for a farm free of MAP. Thus, a net cash flow of $8,255 minus the cost of 
implementing the control option implies that there are no losses caused by JD.  
 In reality, producers may halt a control program if there are no test-positive animals in 
their herd, but the disease would resurface due to undetected infected animals remaining or 
reintroduced into the herd. Table 2.7 shows the lag between the period of MAP elimination and 
the last period of detecting test-positive animals. Given the lag between those periods, it is 
important for producers to keep screening their herd using a MAP test after eliminating the last 
test-positive animals in order to eliminate the disease entirely. However, the ELISA test may not 
be efficient for this monitoring due to the imperfect test specificity, which generates false-
positive test results in the herd free of MAP. Moreover, with the low test sensitivity of the 
ELISA test, infected animals may escape detection and infect many other animals before they are 
identified. Therefore, the FC test, which has near-perfect test specificity and high test sensitivity, 
is recommended even though the FC test is more expensive with slower results than the ELISA 
                                                 
26
 Note that the NPV in this study is the sum of discounted net cash flows. 
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test. In short, a combination of improved hygiene management and test-and-cull using either an 
annual or biannual FC test is highly recommended since these are the most and second most 
cost-effective control options considered in this study.  
 The empirical results show the number of animals infected with MAP and animals in the 
subclinical and clinical stages of JD increases during the planning duration of 50 years in the 
absence of a control program as in previous studies (Groenendaal and Galligan, 2003, 
Groenendaal et al., 2002). However, in practice, it could be possible to observe that even in the 
absence of an active control program, elimination of JD, though not necessarily of the causal 
pathogen MAP, has been successful in some infected herds. There could be several reasons for 
this discrepancy between field experience and our empirical results. The most probable 
explanation is that it is unlikely that a farm with a serious production problem would not engage 
in some form of implicit control. Therefore, low producing and sick cows are culled regardless 
of the causation and it could, in effect, eliminate JD, though animals infected with the causal 
pathogen MAP may still remain in the herd.  
 In sharp contrast, although our empirical results imply that the causal pathogen 
MAP can be eliminated from the herd entirely, which is consistent with previous studies 
(Groenendaal and Galligan, 2003, Groenendaal et al., 2002), in practice complete elimination is 
generally difficult to accomplish. For example, in Canada or the U.S., we could not find an 
evidence to prove that a control program successfully eliminates MAP and JD. There are two 
possible explanations for this. One is that most producers who have a JD problem have initiated 
a control program only recently, as Canada and the U.S. only created a national voluntary control 
program in 2005 and 2002, respectively. Given that the elimination of MAP and JD requires a 
long-term plan, as shown in Table 2.7, more time might be required to document the success of 
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MAP and JD control strategies. Another is that elimination of MAP and JD in our empirical 
results could be due to the fact that the potential risk of stochastic re-introduction of MAP (e.g., 
via purchased animals or humans with contaminated clothing) which, given the lack of 
information on this risk assessment, is ignored in this study.  
Conclusion 
This study presented a conceptual framework for developing an infectious disease control model 
in livestock which is applied as a discrete optimal control model to evaluate the long-term 
feasibility and profitability of various control methods for the causal pathogen MAP which 
causes Johne’s disease in dairy herds. Results show that elimination of the disease requires a 
long-term plan with implementation of at least one of the control strategies. Any MAP control 
method yields a higher NPV of the farm’s net cash flow compared to no control. Implementing 
either additional calf-hygiene management or test-and-cull using a FC test can control the 
disease, but these are most effective when combined with each other in reducing the infection 
rate in MAP-infected herds.  
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CHAPTER 3 
ECONOMIC ANALYSIS OF MYCOBACTERIUM AVIUM SUBSPECIES PARATUBERCULOSIS VACCINES IN 
DAIRY HERDS 
 
Abstract 
Johne’s disease, or paratuberculosis, is a chronic infectious enteric disease of ruminants, caused 
by infection with Mycobacterium avium ssp. paratuberculosis (MAP). Given the absence of a 
fail-safe method of prevention or a cure, Johne’s disease can inflict significant economic loss on 
the U.S. dairy industry, with an estimated annual cost of over $200 million. Currently available 
MAP control strategies include management measures to improve hygiene, culling MAP 
serologic- or fecal-positive adult cows, and vaccination. Although the two first control strategies 
have been reported to be effective in reducing the incidence of MAP infection, the changes in 
herd management needed to conduct these control strategies require significant effort on the part 
of the dairy producer. On the other hand, vaccination is relatively simple to apply and requires 
minor changes in herd management. Despite these advantages, only 5% of U.S. dairy operations 
use vaccination to control MAP. This low percentage of adaption of this technology is due to 
limited information on its cost-effectiveness and efficacy and some important inherent 
drawbacks associated with current MAP vaccines.  
This study investigates the epidemiological impacts and economic values of MAP 
vaccines in various stages of development. We create scenarios for the potential epidemiological 
impacts of MAP vaccines, and then estimate economically justifiable values at which vaccines 
become economically beneficial to dairy producers such that a net present value (NPV) of a 
farm’s net cash flow can be higher than the NPV of a farm employing no control or alternative 
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non-vaccine controls. Any vaccination with either low or high efficacy considered in this study 
yields a higher NPV compared to no control. Moreover, high-efficacy vaccines generate an even 
higher NPV compared to a farm that employs alternative controls, making vaccination 
economically attractive. Two high-efficacy vaccines are particularly effective in MAP control 
and NPV maximization. One is a high-efficacy vaccine that reduces susceptibility to MAP 
infection. The other is a high-efficacy vaccine that has multiple efficacies on the dynamics of 
MAP infection and disease progress. Only one high-efficacy vaccine, in which the vaccine is 
targeted at reducing MAP shedding and the number of clinical cases, is not economically 
beneficial to dairy producers compared to an alternative non-vaccine control, when their herds 
are highly infected with MAP.  
  
Introduction  
Johne’s disease (JD), or paratuberculosis, is a chronic enteric disease of ruminants, caused by 
infection with Mycobacterium avium ssp. paratuberculosis (MAP). JD is one of the most serious 
infectious diseases in dairy cattle given that it produces considerable economic losses and that, at 
present, there is no cure or fail-safe prevention. MAP infection routes in dairy cattle include 
intrauterine infection, postpartum infection via fecal-oral contact and the uptake of MAP-
contaminated colostrum and milk (Sweeney, 1996, USDA, 1997, Benedictus et al., 2008). MAP 
infection normally occurs very early in the life of dairy cattle, but clinical symptoms of JD are 
most commonly seen in adults and include reduced milk production, decreased fertility, 
decreased body-weight, and increased mortality (USDA, 1997, Kudahl and Nielsen, 2009, Smith 
et al., 2009, Aly et al., 2010). Although not all MAP-infected animals develop clinical JD, the 
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production inefficiencies alone can cause significant economic loss for dairy producers (Ott et al., 
1999, Groenendaal et al., 2002, Pillars et al., 2009, Raizman et al., 2009).  
In the U.S., the annual cost to the dairy industry was estimated to be more than $200 
million in 1997 when herd-level MAP prevalence was approximately 22% (USDA, 1997). This 
cost has likely risen as the percent of the U.S. dairy herds infected with MAP has increased to at 
least 68% (USDA, 2008). Moreover, a potential link between MAP and Crohn’s disease (Feller 
et al., 2007, Waddell et al., 2008, Hermon-Taylor, 2009) could further increase the cost of MAP 
to the dairy industry by either prompting strict regulations on dairy production or altering 
consumption of dairy products (Groenendaal and Zagmutt, 2008). These animal and human 
health concerns, together with the economic losses associated with MAP, have increased public 
interest in minimizing the spread of MAP infection and ultimately in eradicating MAP altogether. 
In the absence of effective treatment, calf hygiene management
27
 and test-and-cull
28
 
control strategies are usually recommended and practiced for controlling MAP. Both control 
strategies are economically beneficial for dairy producers compared to no control and are 
reported to be effective in reducing the incidence of MAP infection (Dorshorst et al., 2006, 
Collins et al., 2010, Lu et al., 2010, Sorge et al., 2010, Cho et al., 2011). However, these two 
control strategies require significant added effort on the part of the dairy producer in order to 
achieve effective MAP control. Moreover, test-and-cull often allows a large portion of MAP-
infected animals, particularly infected animals shedding low amounts of MAP, to remain in the 
herd and act as a source of further MAP infection due to the low sensitivity of currently available 
                                                 
27
 Calf hygiene management aims to prevent postpartum infection of calves, the most susceptible animals, by 
providing MAP-free colostrum and milk and avoiding MAP-contamination of the calving area. 
28
 Test-and-cull aims to remove MAP shedding animals, the main source of MAP infection and economic loss, by 
testing adults and slaughtering those found to be test-positive. 
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MAP tests (Collins et al., 2006). The limitations associated with these two-control strategies 
often result in limited adoption or success of the control and elimination of MAP in dairy herds.  
Besides the above control strategies, MAP vaccinations are currently available and 
reported to be cost-effective and provide partial protection by decreasing fecal shedding of MAP 
and reducing the clinical symptoms of JD (Van Schaik et al., 1996, Kalis et al., 2001, Muskens et 
al., 2002, Groenendaal and Galligan, 2003, Rosseels et al., 2006). However, vaccination is the 
least used strategy for controlling MAP because 1) the reported efficacy of the vaccines is varied 
and inconclusive (Harris and Barletta, 2001, Köhler et al., 2001, Muskens et al., 2002); 2) there 
has been only one study investigating the cost-effectiveness of vaccination based on field trial 
data rather than assumptions (Van Schaik et al., 1996); and 3) there are some inherent drawbacks 
associated with current MAP vaccines (Harris and Barletta, 2001, Köhler et al., 2001, Muskens 
et al., 2002).  
Killed MAP vaccines, which are most commonly used worldwide, have been found to 
cause cross-reactivity with bovine tuberculosis (TB) diagnostics, which may potentially result in 
false-positive TB test results for MAP-vaccinated animals. Such false-positive TB tests may 
have a large impact on TB control and therefore MAP vaccination is limited to farms that are 
under close monitoring of regulatory agencies. This, together with limited information on their 
efficacy on MAP control, results in vaccination being used by only 5% of dairy operations in the 
U.S. as a control method for MAP (USDA, 2008). Alternatives such as live vaccines, though 
generally more effective, have the potential risk of spreading viable MAP and therefore have not 
been approved in the U.S. 
Despite such limitations, vaccination has distinct advantages over calf hygiene 
management and test-and-cull. In particular, its ease of application and minimal need for changes 
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in herd management might make it an attractive MAP control strategy. In addition, several types 
of improved MAP vaccines, including subunit-based, DNA-based, and recombinant, are in 
various stages of research, development and evaluation worldwide to overcome the limitations 
associated with currently available vaccines and to enhance efficacy in MAP control (Koets et al., 
2006, Rosseels and Huygen, 2008, Keeble and Walker, 2009). Although reports of the cost-
effectiveness and efficacy of MAP vaccines are not yet fully informed or conclusive, these new 
developments, together with the aforementioned advantages make vaccination of increasing 
interest to the dairy industry. Moreover, in the U.S., potential additional costs caused by cross-
reactivity between certain MAP vaccines and the TB test have been mitigated under a new 
federal order which has removed restrictions on herd movement and TB testing obligations even 
in states where TB has been found (USDA, 2010). Consequently, investigating the economics 
and epidemiological consequences of various MAP vaccines can help the dairy industry to make 
informed choices for MAP control. 
The objective of this study is to evaluate the economic value of various MAP vaccines in 
dairy herds based on their impacts on MAP control. Because information on the efficacy and 
availability of vaccines is limited, we first create scenarios for the potential effects of various 
vaccines on epidemiological progress of MAP infection, and then identify economically 
justifiable values for them to be economically beneficial to dairy producers. To do this, we 
developed a discrete dynamic model that incorporates both economics and different 
epidemiological effects of vaccines on MAP transmission in a dairy herd. This model is coded 
using a mathematical programming and optimization software and empirically solved for a farm 
with alternative initial MAP infection levels to take into account a wide array of dairy farm 
situations. 
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Materials and methods  
A discrete dynamic model is constructed to evaluate the economic value of various MAP 
vaccines based on their epidemiological consequences in MAP control. Because MAP infection 
takes several years to develop into JD, control measures require years to show tangible 
effectiveness. Therefore, evaluating the economic value of vaccination is best accomplished by 
using a dynamic model which incorporates: 1) the dynamics of MAP transmission within a herd 
and 2) the net present value (NPV) of a farm's cash flow over a long-term planning duration. The 
following section presents a MAP transmission model within a dairy herd that incorporates the 
epidemiological impact of various MAP vaccines. Scenarios representing various MAP vaccine 
impacts are then discussed. Lastly, an NPV formula is presented for dairy operations, taking into 
account the economic benefits and costs associated with vaccination. 
 
MAP transmission model 
Animal compartment model is developed from a previous multi-group model that 
described MAP transmission in a dairy herd (Lu et al., 2008, Mitchell et al., 2008, Lu et al., 2010, 
Cho et al., 2011). This animal compartment model is described in Figure 3.1, where the 
definitions of symbols are presented in Table 3.1. In Figure 3.1, animals within a herd are 
grouped into discrete and disjoint compartments according to their 1) infection state, 2) age with 
6-month time steps, and 3) vaccination state. Animal infection states of MAP in a dairy herd are 
classified as: susceptible, resistant, transient, latent, low-shedding, and high-shedding. Animals 
in susceptible and resistant states are non-infected (free of MAP infection), whereas animals in 
transient, latent, low-shedding, and high-shedding states are infected with MAP. Animals in the 
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transient state do not show signs of JD and shed MAP transiently at a low level shortly after 
initial MAP infection (Whitlock et al., 2000). Animals in the latent state also do not show signs 
of JD, and shed no MAP. Animals in the low-shedding state are in a subclinical stage of JD and 
shed low levels of MAP ≤ 30 cfu/g (Whitlock et al., 2000), whereas animals in the high-shedding 
state are potentially showing clinical signs of JD and shed high levels of MAP >30 cfu/g 
(Whitlock et al., 2000).  
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Figure 3.1. Animal compartment model, with the top segment representing no vaccination and 
the bottom segment representing vaccination across animal groups 
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Table 3.1. Definition of symbols in the animal compartment model describing animal movements 
and Mycobacterium avium ssp. paratuberculosis transmission within a herd 
Symbol Definition Value
1 
Reference 
 Exit rate of high-shedding cows due to the clinical signs 0.25
 
Whitlock et al., 2000 
 Exit rate of unvaccinated susceptible calves due to aging Varies
a 
Calculated 
 Exit rate of vaccinated susceptible calves due to aging Variesb Calculated 
 Vertical MAP transmission rate Varies Calculated 
 Horizontal MAP transmission rate Varies Calculated 
a Exit rate of cows due to death, productivity, other diseases Varies
 
Calculated 
b Birth rate for female calves 0.215
 
USDA, 2007 
c Exit rate of calves due to death 0.046
 
USDA, 2007 
h Exit rate of heifers due to death 0.009 USDA, 2007 
c Exit rate of calves due to aging and disease progress 0.954
c 
Calculated 
h Exit rate of heifers due to aging and disease progress 0.991
d 
Calculated 
 Exit rate of latent cows due to disease progress 0.5 Mitchell et al., 2008 
 Exit rate of low-shedding cows due to disease progress 0.165 Van Schaik et al., 2003a 
e Vaccine efficacy in reducing the number of clinical cases 0-1 Defined 
e Vaccine efficacy in reducing MAP shedding level 0-1 Defined 
e Vaccine efficacy in reducing susceptibility 0-1 Defined 
e Vaccine efficacy in prolonging the latent period 0-1 Defined 
e
Vaccine efficacy in slowing progression from low to high 
shedding 
0-1 Defined 
p Proportion of susceptible calves vaccinated 0-1 Defined 
1
 Values are 6-month basis. 
a
 c represents animal movements for unvaccinated susceptible calves due to aging.  
b
 ce represents animal movements for unvaccinated susceptible calves due to aging.  
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c
 cc=0.954 represents animal movements for infected calves due to either aging or 
infection progress: all calves 6 to 12 month old in the latent state become heifers 12 to 18 month 
old in the latent state for the next time period due to aging. Thus, the rate c representing this 
movement is 1-c where c is the death rate of calves. On the other hand, all calves 6 to 12 
month old in the transient state become heifers 12 to 18 month old in the latent state for the next 
time period due to infection progress. Therefore, this movement can also be represented by c = 
1-c.  
d
 hh=0.991 represents animal movements for infected heifers due to either aging or 
infection progress, with the same reason as c representing animal movements for infected calves 
due to either aging or infection progress.  
 
Animal age is closely related to susceptibility to infection and duration of infection states. 
In a dairy herd, animals are typically susceptible to infection up to the age of 12 months (Collins 
and Morgan, 1991, Sweeney, 1996, Whitlock and Buergelt, 1996) and then become resistant 
afterwards. Though some animals born to infected dams may be directly infected with MAP via 
intrauterine infection (Sweeney et al., 1992b), most likely susceptible animals are infected 
following contact with MAP from infected animals (Sweeney et al., 1992a, Whitlock et al., 
2005a) and in contaminated environments (USDA, 1997). These newly infected animals enter 
the transient state, which often develops within a few days of infection and continues up to 6 
months (Rankin, 1961). Given the duration of susceptible and transient states, animals in this 
state are typically younger than 18 months old. The latent state generally occurs following the 
transient state and continues for a long duration, but animals older than 24 months in this state 
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may begin to enter the low-shedding state and then the high-shedding state as the disease 
progresses.  
Although there is some variation in the duration of infection states, 14 different infection 
and age classifications i  I = {1,...,14} are defined to describe the above relationship between 
MAP infection progress and animal age: calves 0 to 6 month old in susceptible (i = 1) or 
transient state (i = 2), calves 6 to 12 month old in susceptible (i = 3), transient (i = 4), or latent (i 
= 5) state; heifers 12 to 18 month old in resistant (i = 6), transient (i = 7), or latent (i = 8) state, 
heifers 18 to 24 month old in resistant (i = 9) or latent (i = 10) state, and adult cows older than 24 
months in resistant (i = 11), latent (i = 12), low-shedding (i = 13), or high-shedding (i = 14) state.  
In order to examine the impact of MAP vaccines, animals are further classified into their 
vaccination state, unvaccinated or vaccinated, the number of which are represented respectively 
as Xi and Vi in Figure 3.1 for 14 different infection and age classifications i  I = {1,...,14}. In 
this model, some newborn calves enter the herd as non-infected, susceptible, calves (X1 and V1), 
whereas the others (X2 and V2) directly enter the transient state at the time of birth via 
intrauterine infection, which is represented by the rate as shown in Figure 3.1. All calves, 
heifers, and adult cows are assumed to exit the herd at rates c, h, and a in Figure 3.1, 
respectively. In addition, all high-shedding cows exit the herd at an additional rate due to 
clinical symptoms of JD. All remaining animals in each compartment for the current time period 
are assumed to move to an adjacent compartment for the next time period due to aging 
ch), infection with MAP ), or infection progress ch)
29
. An arrow in Figure 
                                                 
29
 In the model, the rates c andh represent an animal movement for infected calves and heifers, respectively, due 
to either aging or infection progress. For example, all calves 6 to 12 month old in the latent state become heifers 12 
to 18 month old in the latent state for the next time period due to aging. Thus, the rate c representing this movement 
is 1-c where c is the death rate of calves. On the other hand, all calves 6 to 12 month old in the transient state 
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3.1 indicates this movement. The equations of motion that represent the animal compartment 
model of Figure 3.1 are shown in Appendix. 
 Because revaccination or boosting has been reported to be ineffective to enhance an 
animal's ability to resist MAP infection (Harris and Barletta, 2001), only single vaccination of 
newborn calves is modeled in this study. In Figure 3.1, a proportion of newborn calves are 
vaccinated with parameter p (0 p 1) where p = 0 indicates that no calves are vaccinated, 
whereas p = 1 indicates that all calves are vaccinated. Once newborn calves are vaccinated, they 
move along the vaccinated animal compartments at the bottom of Figure 3.1, whereas 
unvaccinated newborn calves move along the unvaccinated animal compartments at the top of 
Figure 3.1. For the sake of model brevity, all new born calves are assumed to be vaccinated (p = 
1) when producers implement vaccination as a control strategy for MAP. 
The MAP infection routes of both intrauterine infection (vertical transmission) and 
postpartum infection (horizontal transmission) are considered in Figure 3.1. Vertical MAP 
transmission due to infected dams determines the number of transient calves 0 to 6 month old (X2 
and V2) and is formulated in the vertical transmission rate  in Figure 3.1: 
 12 12 12 13 13 13 14 14 14( ) [ { ( ) ( )} { ( ) ( )} { ( ) ( )}]bt X t V t X t V t X t V t           (3.13) 
where bis the birth rate of female calves, and , , and (Table 3.2) are the proportion of 
calves infected in-utero by latent (X12, V12), low-shedding (X13, V13), or high-shedding (X14, V14) 
dams at time t, respectively. These parameters (, , and  may vary for unvaccinated and 
vaccinated infected dams. However, given the lack of information on these potential differences, 
                                                                                                                                                             
become heifers 12 to 18 month old in the latent state for the next time period due to infection progress. Therefore, 
this movement can also be represented by c = 1-c. 
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the intrauterine transmission parameters are assumed to be identical for both unvaccinated and 
vaccinated infected dams. 
 
Table 3.2. Definition of parameters in vertical and horizontal infection transmission rate formulas   
Symbol Definition Value
1 
Reference 
r
Transmission rate between transient 
animals and susceptible calves 
0.5 Lu et al., 2008 

Transmission rate between low-shedders 
and susceptible calves 
1.0 Lu et al., 2008 

Transmission rate between high-shedders 
and susceptible calves  
5.0 Lu et al., 2008 
12
Portion of newborn calves infected at birth 
by latently infected dams 
0.15 Sweeney et al., 1992b 

Portion of newborn calves infected at birth 
by low-shedding dams 
0.15 Whitlock et al., 2005a 

Portion of newborn calves infected at birth 
by high-shedding dams 
0.17 Whitlock et al., 2005b 
1
 Values are 6-month basis. 
 
 Susceptible calves (X1, X3, V1, V3) may be infected by horizontal MAP transmission via 
fecal-oral contact, and the uptake of MAP-contaminated colostrum and milk: infection by 
transiently shedding calves (X2, X4, X7, V2, V4, V7) at the same housing site (calf-calf transmission) 
or by adult shedding cows (X13, X14, V13, V14) through direct fecal-oral transmission and indirect 
transmission via contaminated colostrum and milk (cow-calf transmission). To keep the 
modeling process manageable, three transmission rates Tr, 13, and 14 (Table 3.2) are used to 
represent the multiple transmission routes: calf-calf transmission (Tr) and cow-calf transmission 
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by low (13) and high (14) shedding cows. The force of infection for unvaccinated susceptible 
calves (X1, X3) is formulated as in Figure 3.1: 
 
2 4 7 13 13 14 14
2 4 7 13 13 14 14
( ) { ( ) ( ) ( )} ( ) ( )
(1 )[ { ( ) ( ) ( )} ( ) ( )]
Tr
Tr
t X t X t X t X t X t
e V t V t V t V t V t
   
  
    
     
 (3.2) 
where potential vaccine efficacy in reducing fecal shedding level is represented by parameter e 
(0 e1): e= 0 indicates that no vaccination is implemented or a vaccine has no decreasing 
effect on MAP shedding, whereas e= 1 indicates that a vaccine completely prevents MAP 
shedding. On the other hand, the force of infection for vaccinated susceptible calves (V1, V3) is 
modeled ase in Figure 3.1 to represent potential vaccine efficacy in reducing 
susceptibility e (0 e1): e= 0 indicates that a vaccine has no reducing effect on 
susceptibility to infection, whereas e1 indicates that a vaccine completely prevents 
postpartum MAP infection. 
In addition to reducing MAP shedding levels and susceptibility to infection, three other 
vaccine efficacies are considered for either current or next generation vaccines. These efficacies 
include prolonging the latent period of infected animals by delaying fecal shedding, slowing the 
progression of infectious animals from low- to high-shedding, or decreasing the number of 
clinical JD cases (Harris and Barletta, 2001, Rosseels et al., 2006, Rosseels and Huygen, 2008, 
Romano and Huygen, 2009). These potential efficacies are represented by the parameters 
eeand e in Figure 3.1, respectively.  
 
Scenarios of MAP vaccine efficacy 
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 Five possible efficacies are assumed for MAP vaccines (Figure 3.1): reduction of 
susceptibility (e), reduction of MAP shedding level (e), slower progression from latency to low 
shedding (e), slower progression from low to high shedding (e), and a slower progression to 
clinical JD status (e). These efficacies range from 0, not effective at all, to 1, fully effective. 
Because information on MAP vaccine efficacies is limited, specific values for the parameters 
listed above are not fixed; instead, each efficacy is assigned a representative value of either 0.3 
(relatively low efficacy) or 0.9 (relatively high efficacy). The economic values of vaccines with 
these two representative values can be used as reference values for those vaccines having 
different levels of efficacy. 
The eight scenarios in Table 3.3, which comprise various combinations of vaccine 
efficacies, are developed for representing the potential impact of different types of vaccines on 
the epidemiological process of MAP. These scenarios allow us to compare different 
epidemiological impacts of current and possibly next generation vaccines on MAP control. 
Scenarios 1 and 2 represent vaccines with low- and high-efficacy levels, respectively, which 
specifically target reduction of susceptibility (perhaps the most desirable feature of MAP 
vaccines). Scenarios 3 and 4 represent vaccines with low- and high-efficacy values, respectively, 
for the vaccine effects reported in previous studies (Van Schaik et al., 1996, Kalis et al., 2001, 
Muskens et al., 2002, Groenendaal and Galligan, 2003, Rosseels et al., 2006), including decrease 
of fecal MAP shedding and reduction of clinical JD symptoms. Scenarios 5 to 8 represent 
vaccines having other multiple efficacies that could be produced by some of the currently 
available or next generation vaccines.  
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Table 3.3. Scenarios of Mycobacterium avium ssp. paratuberculosis vaccine efficacy 
Scenario Description Value 
1 Vaccine decreases susceptibility of susceptible calves e =0.3 
2  e =0.9 
   
3 Vaccine reduces shedding level and the number of 
clinical Johne's disease (JD) cases 
e =e =0.3 
4 e =e =0.9 
   
5 Vaccine delays the onset of low shedding and slows the 
progression from low to high shedding 
e =e =0.3 
6 e =e =0.9 
   
7 Vaccine reduces MAP shedding level, delays the onset 
of low shedding and progression from low to high 
shedding, and decreases the number of clinical JD cases 
e =e =e = 
e =0.3 
8 
e =e =e = 
e =0.9 
 
Net present value 
Given a set of epidemiological
30
 constraints, the producer objective is to maximize the 
expected NPV from the sales of milk and cull cows for slaughter by deciding upon a choice of 
vaccination in Table 3.3. Although not all infected animals show clinical JD symptoms, this 
study assumes that animals in the low-shedding state show decreased milk production and body 
weight. As these animals progress to the high-shedding state, they are assumed to show 
considerable reduction in milk production and body weight, and have a higher mortality rate. The 
expected NPV of a producer’s net cash flow from the sales of milk and cull cows for slaughter is 
specified as: 
                                                 
30
 Epidemiological constraints are the equations of motion in Appendix 1 describing the epidemiological process of 
Johne's disease described in Figure 3.1. 
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 (3.3) 
In Equation (3.3), resistant (X11 and V11) and latent (X12 and V12) cows are expected to 
have normal milk production (Qmilk) and body weight (Qcull), Low-shedding cows (X13 and V13) 
and high-shedding cows (X14 and V14), due to the disease, are expected to have lower milk 
production, (1L)Qmilk and (1H)Qmilk respectively, and lower body weight, (1L)Qcull and 
(1H)Qcull respectively, where the parameters L, H, L, and H represent milk production and 
body weight reductions due to JD (Table 3.4). In addition to milk and weight losses, high-
shedding cows can exit the herd due to clinical JD symptoms, but these cows are assumed to be 
freely disposal instead of selling in market. 
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Table 3.4. Definition of variables and parameters used in the net present value equation 
Rate Description Value
1 
Reference 
Ccalf Base operating cost of raising a calf  $395.00
a 
Karszes et al., 2008 
Ccow Base operating cost of raising a cow $1231.46 USDA, 2003-2007 
Cheifer Base operating cost of raising a heifer $395.00
a 
Karszes et al., 2008 
Mvaccine Maximum vaccination cost per dose Varies Calculated 
Ncalf Number of calves Varies Calculated 
Ncow Number of cows 100 Calculated 
Nheifer Number of heifers Varies Calculated 
Pcull Cull-cow price per kg $1.0556 USDA, 2003-2007 
Pmilk Milk price per kg $0.3393 USDA, 2003-2007 
Psale Sale price of a one year old animal  $867
b
 Karszes et al., 2008
 
Qcull Average cull cow weight 680.4 kg USDA, 2003-2007 
Qmilk Average milk production per cow 4408.7 kg USDA, 2003-2007 
r Discount rate  0.02
 
Assumed 
T Total follow up time of a dairy farm 100 Assumed 
H Production adjustment factor for high-shedders  0.1
c 
Groenendaal et al., 2002 
L Production adjustment factor for low-shedders 0.05
c 
Groenendaal et al., 2002 
H Cull-weight adjustment factor for high-shedders 0.1 Assumed 
L Cull-weight adjustment factor for low-shedders 0.05 Assumed 
1
 Values are 6-month basis. 
a. For the sake of simplicity, all heifer-raising operating costs for two years, $1580 per heifer, are 
evenly assigned to the calf- and heifer-rearing activities. 
b
 Sale price of a one year old animal is assumed to be identical to total cost of raising 
replacement heifer up to one year.  
c
 Production reduction due to Johne's disease has been reported 5% to 20%. 
 
 84 
 
The entire herd is assumed to be liquidated at the beginning of the terminal year (T = 50). 
For the sake of model brevity, all remaining cows in the terminal years are sold at the price of 
healthy cows. This is a reasonable assumption given that, with effective controls, no cows will 
show clinical symptoms of JD at the end of the 50 year period. Young stock is all sold at the 
price of one year old animals, the average age of young stock. The variables and parameters in 
Equation (3.3) are presented in Figure 3.1 (animal compartments) and Tables 3.1 (a, b, c, and 
h) and 3.4 (all other parameters). 
Because information on retail price of the vaccines is unavailable, Equation (3.3) includes 
a variable (Mvaccine) representing the maximum vaccination cost per dose (MVC) for new-born 
calves. This MVC is determined endogenously in the optimization process by equating the NPV 
under vaccination to the NPV under an alternative control strategy: 1) the no-control alternative 
or 2) the best non-vaccine alternative. This allows us to obtain the uppermost cost level of 
vaccination, or MVC, that the farmer would be willing to pay for vaccination in order for them to 
be indifferent between applying vaccination and either alternative control strategy, as illustrated 
in Figure 3.2. In other words, a vaccination that cost less than the MVC generates a higher NPV 
to the farm than the NPV obtained using the no-control alternative or the best non-vaccine 
alternative. A positive MVC implies that there is a positive gross return that can be shared by a 
dairy producer (profit and implementation cost if any) and a vaccine company (profit and 
production cost). Conversely, a negative MVC implies that the vaccination is economically 
unattractive to a dairy producer because it generates a lower NPV than the no-control or the best 
non-vaccine alternative cases. 
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Figure 3.2. Maximum cost level of a vaccination at which farmers are indifferent between 
applying vaccination and either the no-control alternative or the best control alternative 
(Improved hygiene with test-and-cull using annual fecal culture test) 
 
The NPV with the best non-vaccine alternative were obtained from our earlier study 
(Cho et al., 2011). This previous study utilized unvaccinated animal compartments at the top of 
Figure 3.1, to examine the cost-effectiveness of various MAP control options over the 50-year 
simulation period which included 1) improved hygiene, 2) advanced hygiene, 3) test-and-cull 
using annual fecal culture test, 4) test-and-cull using annual enzyme-linked immunosorbent assay 
(ELISA) test, 5) test-and-cull using biannual fecal culture test, 6) test-and-cull using biannual 
ELISA test, 7) improved hygiene with test-and-cull using annual fecal culture test, 8) improved 
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hygiene with test-and-cull using annual ELISA test, 9) improved hygiene with test-and-cull 
using biannual fecal culture test, 10) improved hygiene with test-and-cull using biannual ELISA 
test, 11) advanced hygiene with test-and-cull using annual fecal culture test, 12) advanced 
hygiene with test-and-cull using annual ELISA test, 13) advanced hygiene with test-and-cull 
using biannual fecal culture test, and 14) advanced hygiene with test-and-cull using biannual 
ELISA test.  
This earlier study (Cho et al., 2011) utilized the same parameter values for the animal 
compartment model (Figure 3.1) and NPV equation (Equation 3.3) described in this study with 
the exception that the present study assumes a fixed herd size of 100 cows, whereas the previous 
study allowed herd size variation of 80 cows (minimum herd requirement) to 100 cows 
(maximum farm capacity), which allowed heavy culling of animals for test-and-cull strategy. 
The results of the previous study showed that the most cost-effective control option for MAP 
control was improved hygiene management and test-and-cull using an annual fecal culture test. 
Therefore, we used this control option as the best alternative to vaccination, which is the main 
focus of this study.  
Because a mean true prevalence level of 10% MAP infection within a dairy herd is 
commonly assumed (Wells et al., 2002, Van Schaik et al., 2003b, Dorshorst et al., 2006), two 
initial MAP infection levels (10%, and 20%) are considered for the baseline farm, to account for 
the majority of dairy farm situations. Each infection level represents a percentage of MAP 
infected adult cows (sum of latent, low-shedding, and high-shedding cows) per all adult cows in 
a herd, and these initial MAP infection levels are obtained from a simulation of unvaccinated 
animal compartments at the top of Figure 3.1: an initial infection distribution among 
unvaccinated animal groups is simulated for a farm with an initial herd of 99 non-infected cows 
 87 
 
and 1 latently infected cow, with no control implemented. The initial conditions for the state 
variables for a farm with two different MAP infection levels are drawn from time-points in this 
simulation that matched the desired infection level. These initial conditions are also identical to 
that used in Cho et al. (2011).  
The model described in this section is coded using the General Algebraic Modeling 
System (version 22.5, GAMS Development Corporation, Washington, DC) and empirically 
solved for a farm with two possible MAP infection levels for a long-term, 50-year simulation 
period. The result of this optimization would allow identification of both epidemiological 
consequences of the eight vaccination options and the MVC value which makes a certain 
vaccination option economically more attractive in the long term, rather than either no control or 
the best alternative. 
 
Results and discussion 
In the absence of MAP control, simulation of unvaccinated animal compartments (the top of 
Figure 3.1) shows that MAP prevalence increases continuously (Figure 3.3), as reported in 
previous studies (Groenendaal et al., 2002, Groenendaal and Galligan, 2003). With any type of 
low-efficacy vaccines, elimination
31
 of MAP is not observed in the 50-year simulation period 
given initial infection levels of 10% or 20% (Table 3.5). Only a low-efficacy vaccine with 
multiple effects on the dynamics of MAP infection and progress (Scenario 7)
32
 will control MAP 
at a fairly constant rate after 5 years of vaccination (Figure 3.4). All other low-efficacy vaccines 
result in an increase in MAP prevalence (Figure 3.4), especially those targeted at reducing MAP-
                                                 
31
 MAP is considered to be eliminated when its prevalence rate is less than 1%. 
32
 This low-efficacy vaccine is targeted at reducing MAP shedding level, delaying the onset of shedding and 
progression from low to high shedding, and decreasing the number of clinical JD cases. 
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shedding level and the number of clinical JD cases (Scenario 3), and delaying the onset of MAP 
shedding and slowing the progression from low to high shedding states (Scenario 5). These 
vaccination scenarios result in a rapid increase of MAP prevalence because they only have 
partial and limited effects on reducing sources of MAP infection, which results in a slower 
elimination process than the MAP infection process within a herd.  
 
Figure 3.3. Dynamics of Mycobacterium avium ssp. paratuberculosis (MAP) infection without 
control: the portions of latent, low-shedding, high-shedding adult cows in the herd with a total of 
100 cows and the initial MAP prevalence of 10% and 20% 
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Table 3.5. Expected elimination period of Mycobacterium avium ssp. paratuberculosis (MAP) 
for a herd with vaccination and the initial infection level of 10% and 20% 
Scenario 
Expected elimination
1
 period of MAP 
Initial MAP infection level of 10% Initial MAP infection level of 20% 
1 Never Never 
2 10.5 years 13 years 
3 Never Never 
4 22.5 years 26 years 
5 Never Never 
6 29 years 34 years 
7 Never Never 
8 17.5 years 20 years 
1
 MAP is considered to be eliminated when its prevalence rate is less than 1%, which implies that 
total number of MAP-infected cows is less than one given a fixed herd size of 100 cows. 
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Figure 3.4. Impact of low efficacy vaccines on the dynamics of Mycobacterium avium ssp. 
paratuberculosis (MAP) infection: the portion of latent, low-shedding, high-shedding cows in a 
herd of 100 and the initial MAP prevalence of 10% and 20% 
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In sharp contrast, all high-efficacy vaccines successfully eliminate MAP within 29 years 
and 34 years for a herd with initial infection levels of 10% and 20%, respectively (Table 3.5), 
though none of these high-efficacy vaccines eliminates MAP quicker than the best alternative of 
improved hygiene management and test-and-cull using an annual fecal culture test, which 
eliminated MAP from the herd within 8 years for both MAP prevalence levels (Cho et al., 2011). 
Impact of these high-efficacy vaccines on the dynamics of MAP infection (Figure 3.5) suggests 
that the most effective vaccine scenario for eliminating MAP is a high-efficacy vaccine that 
reduces susceptibility of susceptible calves (Scenario 2), which results in eliminating MAP 
within 10.5 years (initial prevalence of 10%) and 13 years (initial prevalence of 20%), as shown 
in Table 3.5 and Figure 3.5. This finding implies that the prevention effect is the most useful 
possible effect of vaccines in MAP control.  
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Figure 3.5. Impact of high efficacy vaccines on the dynamics of Mycobacterium avium ssp. 
paratuberculosis (MAP) infection: the portions of latent, low-shedding, high-shedding cows in a 
herd of 100 cows and the initial MAP prevalence of 10% and 20% 
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The second most effective vaccine scenario for eliminating MAP is a high efficacy 
vaccine with multiple effects on the dynamics of MAP infection and progress (Scenario 8)
33
, 
eliminating MAP within 17.5 years (initial prevalence of 10%) and 20 years (initial prevalence 
of 20%), as shown in Table 3.5 and Figure 3.5. Given the multiple efficacies associated with this 
vaccine, a large portion of infected cows are non-clinically infected (latent cows), which does not 
cause economic loss. In addition, the aforementioned low-efficacy (Scenario 7 in Figure 3.4) 
with the same epidemiological impact with this high-efficacy vaccine in Scenario 8, is the only 
low-efficacy vaccine that controls MAP at a fairly constant rate. Therefore, dairy producers 
might want to control MAP using this low-efficacy vaccine (Scenario 7 in Figure 3.4) among all 
available vaccines when only low-efficacy vaccines are available, whereas they might want to 
control MAP using a high-efficacy vaccine (Scenario 2 in Figure 3.4) that reduces the 
susceptibility of eligible calves if high-efficacy vaccines become available. 
Two other high efficacy vaccines also eliminate MAP. One vaccine is targeted at 
reducing both the shedding level and the number of clinical JD cases (Scenario 4) within 22.5 
years (initial prevalence of 10%) and 26 years (initial prevalence of 20%), as shown in Table 3.5 
and Figure 3.5. The other is targeted at delaying the onset of shedding and slowing the 
progression from low to high shedding (Scenario 6) within 29 years (initial prevalence of 10%) 
and 34 years (initial prevalence of 20%), also shown in Table 3.5 and Figure 3.5. Although the 
vaccine in Scenario 6 takes longer to eliminate MAP than that in Scenario 4, the portion of latent 
cows among all infected cows in Scenario 6 is much larger. The fact that latent cows do not 
cause economic loss, coupled with the epidemiological consequences of the second most 
                                                 
33
 This high-efficacy vaccine is targeted at reducing MAP shedding level, delaying the onset of shedding and 
progression from low to high shedding, and decreasing the number of clinical JD cases. 
  
 
 94 
 
effective vaccine in Scenario 8, implies that prolongation of latency and slowed progression from 
low to high shedding may be the more economically beneficial effects of vaccination rather than 
reductions of MAP shedding level and reductions in the number of clinical JD cases. However, 
given the short MAP elimination period associated with Scenario 6, the relative economic benefit 
of the vaccines in Scenarios 4 and 6 is not as clear when considering epidemiological 
consequences alone. The epidemiological impacts of low- and high-efficacy vaccinations in 
Figures 3.4 and 3.5 suggest that the level of efficacy of vaccines are a more important feature of 
vaccination, than either MAP infection level within a herd, or the effects of a vaccine on the 
dynamics of MAP infection. In conclusion, any high-efficacy vaccine shows considerably better 
effects on MAP control compared to any low-efficacy vaccines.  
In this study, the NPV of a MAP-free farm (0% initial infection level) is estimated to be 
$374,270 for the 50-year simulation period with a fixed herd size of 100 cows. On the other hand, 
the NPV of a MAP-infected farm is estimated to be considerably lower at $155,710 (10% initial 
infection level) and $88,819 (20% initial infection level) in the absence of MAP control. These 
low NPV values are not sustainable and imply that a farm would eventually need to engage in 
some type of remedial action as the number of subclinical (low-shedding) and clinical (high-
shedding) cows increase over time, and before JD becomes pervasive in the herd. According to 
Cho et al. (2011), the best control alternative generated an NPV of $345,603 and $336,873
34
, 
which are significantly higher compared to the above NPV of a farm without control, given the 
initial infection level of 10% and 20%, respectively. With MAP vaccinations, the upper-most 
cost level of vaccination, MVC, for the eight MAP vaccination scenarios, are standardized as the 
                                                 
34
 These NPVs were obtained when the herd size of 80 to 100 cows was allowed in order to allow heavy culling of 
test-positive animals under a test-and-cull strategy. 
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average present value per dose are presented in Figures 3.6 and 3.7. These results suggest that 
any MAP vaccination would yield a higher NPV than that using the no-control alternative 
(Figure 3.6), and most of the high-efficacy vaccines have potential to generate a higher NPV 
than using the best alternative (Figure 3.7). 
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Figure 3.6. Maximum vaccination cost per dose (MVC) for Mycobacterium avium ssp. 
paratuberculosis (MAP) vaccine, which makes that vaccination option economically more 
attractive than no control when the initial MAP infection level is 10% or 20% 
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Figure 3.7. Maximum vaccination cost per dose (MVC) for Mycobacterium avium ssp. 
paratuberculosis (MAP) vaccine, which makes that vaccination option economically more 
attractive than the best alternative (improved hygiene management and test-and-cull using an 
annual fecal culture test) when the initial MAP infection level is 10% or 20% 
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Each MVC in Figures 3.6 and 3.7 is the maximum amount dairy producers should be 
willing to pay for implementing each vaccination instead of the no-control alternative or the best 
alternative control not involving vaccination. The high MVC in Figure 3.6 implies that any 
vaccination option has a high potential to be greatly beneficial to dairy producers, compared to 
no control. In particular, two high-efficacy vaccines should be particularly attractive to dairy 
producers: 1) a vaccine that reduces susceptibility to MAP infection (Scenario 2), and 2) a 
vaccine that has multiple efficacies (Scenario 8)
35
. These two scenarios in Figure 3.6 have MVC 
of $223.38 (initial prevalence of 10%) and $282.33 (initial prevalence of 20%), and $222.99 
(initial prevalence of 10%) and $281.83 (initial prevalence of 20%), respectively. These MVC 
imply that JD inflicts an annual cost of $96.03 (=$222.99×43÷100) to $121.18 
(=$282.33×43÷100) per cow in the herd
36
. These two high-efficacy vaccines also have the 
highest MVC of $17.79 (initial prevalence of 10%) and $13.77 (initial prevalence of 20%), and 
$17.40 (initial prevalence of 10%) and $13.27 (initial prevalence of 20%) when compared to the 
best alternative, respectively (Figure 3.7). Considering that these two high-efficacy vaccinations 
are the most effective (Scenario 2) and the second most effective (Scenario 8) vaccination 
options in controlling MAP, as discussed in the previous section, a high-efficacy vaccine that 
reduces susceptibility (Scenario 2) might be the best vaccination option overall, followed by a 
high-efficacy vaccine with multiple efficacies on the dynamics of MAP infection and progress 
(Scenario 8)
37
.  
                                                 
35
 This vaccine targeted at reducing MAP shedding level, delaying the onset of shedding and progression from low 
to high shedding, and decreasing the number of clinical JD cases. 
36
 43 are the number of vaccinated calves per year and 100 are the number of cows in the herd. 
37
 Vaccine targeted at reducing MAP shedding level, delaying the onset of shedding and progression from low to 
high shedding, and decreasing the number of clinical JD cases. 
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In the bottom of Figure 3.7, only one high-efficacy vaccine described in Scenario 4 has a 
negative MPV of -$12.75, which implies that this vaccination always generates a lower NPV 
than that using the best alternative, given the initial infection level of 20%. This implies that the 
vaccine in Scenario 4, in which the vaccine is targeted at reducing MAP shedding level and the 
number of clinical JD cases, may not be economically beneficial to dairy producers when their 
herds are highly infected with MAP. This result also implies that many of the currently available 
MAP vaccines may not be economically attractive compared to the best alternative of improved 
hygiene management and test-and-cull using an annual fecal culture test, when the herd is highly 
infected with MAP. This is because the vaccine in Scenario 4 is designed to represent the 
commonly reported effects of currently available MAP vaccines, which reduces MAP shedding 
level and the number of clinical JD cases. In addition, the negative MVC associated with the 
low-efficacy vaccine scenarios (Figure 3.7) suggest that none of the low-efficacy vaccine 
scenarios can generate a higher NPV compared to the best alternative, given the same infection 
levels, and therefore, they may not be an economically more attractive control method than the 
best alternative. Nevertheless, low-efficacy vaccines have high potential to generate a higher 
NPV compared to the no-control strategy, given that their MVC values are significantly positive 
for all scenarios, as shown in Figure 3.6. 
The MVC values discussed above, however, are maximum values based upon breakeven 
estimates, and do not reflect profit sharing with vaccine developers nor take risk considerations 
into account. Therefore, even though a vaccination has a positive MVC, it may or may not be an 
economically better MAP control method compared to either alternative, since market prices for 
these hypothetical vaccines are not know at this time. For example, the maximum MVC for the 
high-efficacy vaccine in Scenario 2 is reported in Figure 3.7 as $17.79, given the initial infection 
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level of 10%. However, this MVC is not the potential economic benefit of the vaccination for a 
dairy producer relative to the best alternative. In fact, this number represents the potential 
maximum gross return from the vaccination, which would be shared by a dairy producer (profit 
and vaccination cost if any) and a vaccine company (profit and production cost). Therefore, 
whether or not this vaccination would generate a higher economic benefit, in terms of NPV, for a 
dairy producer, than the best alternative is inconclusive given the lack of information on the 
actual cost of the vaccine to the dairy producer. Nevertheless, this vaccination could generate a 
higher NPV of $362,034 and $349,592, compared to using the best alternative ($345,603 and 
$336,873) given an initial infection level of 10% and 20%, respectively, when the cost of the 
vaccination to the dairy producer is zero.  
Although the MVC of the various vaccination scenarios are presented in Figures 3.6 and 
3.7, it is useful to convert these into maximum feasible NPV
38
 of vaccination (Table 3.6). Given 
a constant herd size of 100 cows and a birth rate of female calves of 0.215 per 6-months, the 
maximum feasible annual economic benefit
39
 associated with vaccination compared to either no 
control or the best alternative can be calculated by multiplying a MVC value for a MAP vaccine 
times 43 (=100×0.215×2), which is the number of vaccinated calves per year. Adding the NPV 
of either no control or the best alternative to this annual economic benefit associated with 
vaccination represents the maximum feasible NPV of vaccination. The high-efficacy vaccination 
which decreases susceptibility of susceptible calves has the highest MVC value, (Scenario 2), 
and could generate an NPV of $362,034 and $349,592, which are significantly higher compared 
                                                 
38
 Maximum feasible NPV is the NPV with the vaccination compared to either no control or the best alternative 
when the cost of the vaccination is zero.  
39
 Maximum feasible annual economic benefit is the annual economic benefit with the vaccination compared to 
either no control or the best alternative when the cost of the vaccination is zero. Positive value represents benefit, 
whereas negative value represents loss.  
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to a farm without control with an NPV of $155,710 and $88,819 given the initial infection level 
of 10% and 20%, respectively. These NPVs are also higher compared to a farm employing the 
best alternative (NPV of $345,603 and $336,873)
40
. 
 
Table 3.6. Maximum feasible net present value (NPV) of vaccination given the initial 
Mycobacterium avium ssp. paratuberculosis (MAP) infection level of 10% and 20% 
Scenario 
Maximum feasible NPV
1
 of vaccination 
Initial MAP infection level of 10% Initial MAP infection level of 20% 
1 $297,961 $240,445 
2 $362,034 $349,592 
3 $251,095 $182,412 
4 $349,122 $325,097 
5 $251,372 $193,865 
6 $360,261 $346,609 
7 $311,511 $264,598 
8 $361,674 $349,130 
1
 Maximum feasible NPV is the NPV with the vaccination compared to either no control or the 
best alternative when the cost of the vaccination is zero. 
 
Conclusion 
This study evaluates both the epidemiological consequences and economic value of various 
MAP vaccines in dairy herds, using a discrete dynamic model which incorporates dynamics of 
                                                 
40
 These NPVs were obtained when heavy culling of test-positive animals was allowed in the herds of 80 to 100 
cows from our previous study for maximizing NPVs. 
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MAP transmission within a herd and maximized NPV of the farm's cash flow over a planning 
duration. Eight vaccination scenarios, which comprise various combinations of vaccine efficacies, 
are developed for representing the potential impact on the epidemiological process of MAP of 
different types of vaccines,. These scenarios allow us to compare different epidemiological 
impacts of current and possibly next generation vaccines on MAP control. 
Results show that elimination of MAP requires a long-term plan with implementation of 
at least one of the high-efficacy vaccines. Any vaccination with either low or high efficacy yields 
a higher NPV compared to no control when the cost of these vaccinations is less than their MVC. 
Any high-efficacy vaccines, with the exception of the vaccine targeted at reducing MAP 
shedding level and the number of clinical JD cases (Scenario 4), generates an even higher NPV 
compared to a farm with the best alternative when the cost of these vaccinations is less than their 
MVC. Given the epidemiological consequences and economical benefits of various vaccination 
options, a high-efficacy vaccine that reduces susceptibility (Scenario 2) might be the best 
vaccination option, and a high-efficacy vaccine that has multiple efficacies on the dynamics of 
MAP infection and progress (Scenario 8)
41
 might be the second best vaccination option for dairy 
producers in MAP control.  
  
                                                 
41
 Vaccine targeted at reducing MAP shedding level, delaying the onset of shedding and progression from low to 
high shedding, and decreasing the number of clinical JD cases. 
 103 
 
REFERENCES 
 
Aly, S. S., R. J. Anderson, J. M. Adaska, J. Jiang, and I. A. Gardner. 2010. Association between 
Mycobacterium avium subspecies paratuberculosis infection and milk production in two 
California dairies. J. Dairy Sci. 93(3):1030-1040. 
Benedictus, A., R. Mitchell, M. Linde-Widmann, R. Sweeney, T. Fyock, Y. Schukken,  and R. 
Whitlock. 2008. Transmission parameters of Mycobacterium avium subspecies paratuberculosis 
infections in a dairy herd going through a control program. Prev. Vet. Med. 83(3-4):215-227. 
Cho, J., L. Tauer, Y. Schukken, R. Smith, Z. Lu, and Y. Gröhn. 2011. Compartment Model for 
Controlling Infectious Livestock Disease: Cost-Effective Control Strategies for Johne's Disease 
In Dairy Herds. in Proc. 2011 Agricultural and Applied Economics Association Annual Meeting. 
Agricultural and Applied Economics Association, Pittsburgh, Pennsylvania. 
http://purl.umn.edu/103393. 
Collins, M., V. Eggleston, and E. Manning. 2010. Successful control of Johne's disease in nine 
dairy herds: Results of a six-year field trial. J. Dairy Sci. 93(4):1638-1643. 
Collins, M. and I. Morgan. 1991. Economic decision analysis model of a paratuberculosis test 
and cull program. J. Am. Vet. Med. Assoc. 199(12):1724. 
Collins, M. T., I. A. Gardner, F. B. Garry, A. J. Roussel, and S. J. Wells. 2006. Consensus 
recommendations on diagnostic testing for the detection of  paratuberculosis in cattle in the 
United States. J. Am. Vet. Med. Assoc. 229(12):1912-1919. 
Dorshorst, N., M. Collins, and J. Lombard. 2006. Decision analysis model for paratuberculosis 
control in commercial dairy herds. Prev. Vet. Med. 75(1-2):92-122. 
Feller, M., K. Huwiler, R. Stephan, E. Altpeter, A. Shang, H. Furrer, G. E. Pfyffer, T. Jemmi, A. 
Baumgartner, and M. Egger. 2007. Mycobacterium avium subspecies paratuberculosis and 
Crohn's disease: a systematic review and meta-analysis. Lancet Infect Dis. 7(9):607-613. 
Groenendaal, H. and D. Galligan. 2003. Economic consequences of control programs for 
paratuberculosis in midsize dairy farms in the United States. J. Am. Vet. Med. Assoc. 
223(12):1757-1763. 
 104 
 
Groenendaal, H., M. Nielen, A. Jalvingh, S. Horst, D. Galligan, and J. Hesselink. 2002. A 
simulation of Johne's disease control. Prev. Vet. Med. 54(3):225-245. 
Groenendaal, H. and F. J. Zagmutt. 2008. Scenario Analysis of Changes in Consumption of 
Dairy Products Caused by a Hypothetical Causal Link Between Mycobacterium avium 
subspecies paratuberculosis and Crohn's Disease. J. Dairy  Sci. 91(8):3245-3258. 
Harris, N. B. and R. G. Barletta. 2001. Mycobacterium avium subsp. paratuberculosis in 
Veterinary Medicine. Clin. Microbiol. Rev. 14(3):489-512. 
Hermon-Taylor, J. 2009. Mycobacterium avium subspecies paratuberculosis, Crohn's disease and 
the Doomsday scenario. Gut Pathog. 1(1):1-6. 
Kalis, C. H., J. W. Hesselink, H. W. Barkema, and M. T. Collins. 2001. Use of long-term 
vaccination with a killed vaccine to prevent fecal shedding of Mycobacterium avium subsp 
paratuberculosis in dairy herds. Am. J. Vet. Res. 62(2):270-274. 
Karszes, J., C. Wickswat, and F. Vokey. 2008. Dairy Replacement Programs: Costs & Analysis 
December 2007. Cornell University. 
http://dyson.cornell.edu/outreach/extensionpdf/2008/Cornell_AEM_eb0816.pdf 
Keeble, J. and K. Walker. 2009. Therapeutic vaccine comprising Mycobacterium HSP70. Expert 
Opin Ther Pat. 19(1):95-99. 
Koets, A., A. Hoek, M. Langelaar, M. Overdijk, W. Santema, P. Franken, W. Eden, and V. 
Rutten. 2006. Mycobacterial 70 kD heat-shock protein is an effective subunit vaccine against 
bovine paratuberculosis. Vaccine. 24(14):2550-2559. 
Köhler, H., H. Gyra, K. Zimmer, K. Dräger, B. Burkert, B. Lemser, D. Hausleithner, K. Cussler, 
W. Klawonn, and R. Hess. 2001. Immune reactions in cattle after immunization with a 
Mycobacterium paratuberculosis vaccine and implications for the diagnosis of M. 
paratuberculosis and M. bovis infections. J. Vet. Med., Series B 48(3):185-195. 
Kudahl, A. B. and S. S. Nielsen. 2009. Effect of paratuberculosis on slaughter weight and 
slaughter value of dairy cows. J. Dairy Sci. 92(9):4340-4346. 
Lu, Z., R. Mitchell, R. Smith, J. Van Kessel, P. Chapagain, Y. Schukken, and Y. Grohn. 2008. 
The importance of culling in Johne's disease control. J. Theor. Biol. 254(1):135-146. 
 105 
 
Lu, Z., Y. Schukken, R. Smith, and Y. Grohn. 2010. Stochastic simulations of a multi-group 
compartmental model for Johne's disease on US dairy herds with test-based culling intervention. 
J. Theor. Biol. 264(4):1190-1201. 
Mitchell, R., R. Whitlock, S. Stehman, A. Benedictus, P. Chapagain, Y. Grohn, and Y. Schukken. 
2008. Simulation modeling to evaluate the persistence of Mycobacterium avium subsp. 
paratuberculosis (MAP) on commercial dairy farms  in the United States. Prev. Vet. Med. 83(3-
4):360-380. 
Muskens, J., F. Van Zijderveld, A. Eger, and D. Bakker. 2002. Evaluation of the long-term 
immune response in cattle after vaccination against paratuberculosis in two Dutch dairy herds. 
Vet. Microbiol. 86(3):269-278. 
Ott, S., S. Wells, and B. Wagner. 1999. Herd-level economic losses associated with Johne's 
disease on US dairy operations. Prev. Vet. Med. 40(3-4):179-192. 
Pillars, R., D. Grooms, C. Wolf, and J. Kaneene. 2009. Economic evaluation of Johne's  disease 
control programs implemented on six Michigan dairy farms. Prev. Vet.  Med. 90(3-4):223-232. 
Raizman, E. A., J. P. Fetrow, and S. J. Wells. 2009. Loss of income from cows shedding 
Mycobacterium avium subspecies paratuberculosis prior to calving compared with cows not 
shedding the organism on two Minnesota dairy farms. J. Dairy Sci. 92(10):4929-4936. 
Rankin, J. 1961. The experimental infection of cattle with Mycobacterium Johnei. III. Calves 
maintained in an infectious environment. J Comp Pathol Ther. 71:10-15. 
Romano, M. and K. Huygen. 2009. DNA vaccines against mycobacterial diseases. Expert Rev. 
Vaccines. 8(9):1237-1250. 
Rosseels, V. and K. Huygen. 2008. Vaccination against paratuberculosis. Expert Rev. Vaccines. 
7(6):817-832. 
Rosseels, V., S. Marche, V. Roupie, M. Govaerts, J. Godfroid, K. Walravens, and K. Huygen. 
2006. Members of the 30- to 32-kilodalton mycolyl transferase family (Ag85) from culture 
filtrate of Mycobacterium avium subsp. paratuberculosis are immunodominant Th1-type antigens 
recognized early upon infection in mice and  cattle. Infect. Immun.74(1):202-212. 
 106 
 
Smith, R., Y. Grohn, A. Pradhan, R. Whitlock, J. Van Kessel, J. Smith, D. Wolfgang, and Y. 
Schukken. 2009. A longitudinal study on the impact of Johne's disease status on milk production 
in individual cows. J. Dairy Sci. 92(6):2653. 
Sorge, U., D. Kelton, K. Lissemore, A. Godkin, S. Hendrick, and S. Wells. 2010.  Attitudes of 
Canadian dairy farmers toward a voluntary Johne's disease control  program. J. Dairy Sci. 93(4): 
1491-1499. 
Sweeney, R., R. Whitlock, and A. Rosenberger. 1992a. Mycobacterium paratuberculosis cultured 
from milk and supramammary lymph nodes of infected asymptomatic cows. J. Clin. Microbiol. 
30(1):166. 
Sweeney, R., R. Whitlock, and A. Rosenberger. 1992b. Mycobacterium paratuberculosis isolated 
from fetuses of infected cows not manifesting signs of the disease. Am. J. Vet. Res. 53(4):477. 
Sweeney, R. W. 1996. Transmission of paratuberculosis. Vet. Clin. North Am. Food Anim. Pract. 
12(2):305. 
USDA. 1997. Johne's disease on U.S. Dairy Operations. Animal and Plant Health Inspection 
Service., Washington DC. http://purl.umn.edu/32763. 
USDA. 2003-2007. Agricultural Prices Summary 2003-2007. 
http://usda.mannlib.cornell.edu/MannUsda/viewDocumentInfo.do?documentID=1 003. 
USDA. 2007. Dairy 2007. Part I: Reference of Dairy Cattle Health and Management Practices in 
the United States, 2007. Animal and Plant Health Inspection Service., Washington DC. 
http://www.aphis.usda.gov/animal_health/nahms/dairy/downloads/dairy07/Dairy07_dr_PartI.pdf. 
USDA. 2008. Johne’s Disease on U.S. Dairies, 1991–2007. Animal and Plant Health Inspection 
Service., Washington DC. 
http://www.aphis.usda.gov/animal_health/nahms/dairy/downloads/dairy07/Dairy07_is_Johnes.p
df. 
USDA. 2010. Questions and Answers: Bovine Tuberculosis Federal Order. Animal and Plant 
Health Inspection Service., Washington DC. 
http://www.aphis.usda.gov/publications/animal_health/content/printable_version/faq_bovine_tb_
fed_order.pdf. 
 107 
 
Van Schaik, G., C. Kalis, G. Benedictus, A. Dijkhuizen, and R. Huirne. 1996. Cost-benefit 
analysis of vaccination against paratuberculosis in dairy cattle. Vet. Rec. 139(25):624. 
Van Schaik, G., C. R. Rossiter, S. M. Stehman, S. J. Shin, and Y. H. Schukken. 2003a. 
Longitudinal study to investigate variation in results of repeated ELISA and culture of fecal 
samples for Mycobacterium avium subsp paratuberculosis in commercial dairy herds. Am. J. Vet. 
Res. 64(4):479-484. 
Van Schaik, G., Y. Schukken, C. Crainiceanu, J. Muskens, and J. VanLeeuwen. 2003b. 
Prevalence estimates for paratuberculosis adjusted for test variability using Bayesian analysis. 
Prev. Vet. Med. 60(4):281-295. 
Waddell, L. A., A. Raji , J. Sargeant, J. Harris, R. Amezcua, L. Downey, S. Read, and S. A. 
McEwen. 2008. The zoonotic potential of Mycobacterium avium spp. paratuberculosis: a 
systematic review. Can J Public Health. 99(2). 
Wells, S., R. Whitlock, B. Wagner, J. Collins, F. Garry, H. Hirst, J. Lawrence, W. Saville, and A. 
Naugle. 2002. Sensitivity of test strategies used in the Voluntary Johne's Disease Herd Status 
Program for detection of Mycobacterium paratuberculosis  infection in dairy cattle herds. J. Am. 
Vet. Med. Assoc. 220(7):1053-1057. 
Whitlock, R., R. Sweeney, T. Fyock, and J. Smith. 2005a. MAP super-shedders: Another  factor 
in the control of Johneís disease. in Proc. the 8th International Colloquium on Paratuberculosis. 
Whitlock, R., S. Wells, R. Sweeney, and J. Van Tiem. 2000. ELISA and fecal culture for 
paratuberculosis (Johne's disease): sensitivity and specificity of each method. Vet. Microbiol. 
77(3-4):387-398. 
Whitlock, R., M. Widmann, R. Sweeney, T. Fyock, M. Linde, A. Benedictus, R. Mitchell, and Y. 
Schukken. 2005b. Estimation of parameters on the vertical transmission of Map in a low-
prevalence dairy herd. in Proc. the 8th International Colloquium on Paratuberculosis. 
Whitlock, R. H. and C. Buergelt. 1996. Preclinical and clinical manifestations of 
paratuberculosis (including pathology). Vet. Clin. North Am. Food Anim. Pract. 12(2):345. 
 
  
 108 
 
APPENDIX 
The dynamics of MAP transmission within a herd described in the animal compartment model of 
Figure 3.1 are represented by the following equations of motion:  
14
1 111
( 1) (1 ){ ( )}[ { ( ) ( )}] [1 { ( ) ( )}] ( )b i i ciX t p t X t V t t t X t              [A1] 
 2 2( 1) (1 ) ( ) [1 ( )] ( )c cX t p t X t         [A2] 
 3 1 3( 1) ( ) ( ) [1 { ( ) ( )}] ( )cX t t X t t t X t          [A3] 
 4 1 4( 1) ( ) ( ) [1 ( )] ( )c cX t t X t X t        [A4] 
 5 2 5( 1) ( ) [1 ( )] ( )c c cX t X t X t        [A5] 
 6 3 6( 1) ( ) ( ) [1 ( )] ( )h hX t t X t X t        [A6] 
 7 3 7( 1) ( ) ( ) [1 ( )] ( )h hX t t X t X t        [A7] 
 8 4 5 8( 1) [ ( ) ( )] [1 ( )] ( )c h hX t X t X t X t         [A8] 
 9 6 9( 1) ( ) [1 ( )] ( )h h hX t X t X t        [A9] 
 10 7 8 10( 1) [ ( ) ( )] [1 ( )] ( )h h hX t X t X t X t         [A10] 
 11 9 11( 1) ( ) [1 ( )] ( )h aX t X t t X t      [A11] 
 12 10 12( 1) ( ) [1 { ( ) }] ( )h aX t X t t X t        [A12] 
 13 12 13( 1) ( ) [1 ( ( ) )] ( )aX t X t t X t        [A13] 
 14 13 14( 1) ( ) [1 ( ( ) )] ( )aX t X t t X t        [A14] 
14
1 111
( 1) { ( )}[ { ( ) ( )}] [1 {(1 ) ( ) ( )}] ( )b i i ciV t p t X t V t e t t V t              [A15] 
 2 2( 1) ( ) [1 ( )] ( )c cV t p t V t        [A16] 
 3 1 3( 1) ( ) ( ) [1 {(1 ) ( ) ( )}] ( )cV t t V t e t t V t           [A17] 
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 4 1 4( 1) (1 ) ( ) ( ) [1 ( )] ( )c cV t e t V t V t          [A18] 
 5 2 5( 1) ( ) [1 ( )] ( )c c cV t V t V t        [A19] 
 6 3 6( 1) ( ) ( ) [1 ( )] ( )h hV t t V t V t        [A20] 
 7 3 7( 1) (1 ) ( ) ( ) [1 ( )] ( )h hV t e t V t V t          [A21] 
 8 4 5 8( 1) [ ( ) ( )] [1 ( )] ( )c h hV t V t V t V t         [A22] 
 9 6 9( 1) ( ) [1 ( )] ( )h h hV t V t V t        [A23] 
 10 7 8 10( 1) [ ( ) ( )] [1 ( )] ( )h h hV t V t V t V t         [A24] 
 11 9 11( 1) ( ) [1 ( )] ( )h aV t V t t V t      [A25] 
 12 10 12( 1) ( ) [1 { ( ) (1 ) }] ( )h aV t V t t e V t         [A26] 
 13 12 13( 1) (1 ) ( ) [1 { ( ) (1 ) }] ( )aV t e V t t e V t           [A27] 
 14 13 14( 1) (1 ) ( ) [1 { ( ) (1 ) }] ( )aV t e V t t e V t           [A28] 
where the definitions of parameters and transition rates are presented in Tables 3.1 to 3.2 and the 
vertical () and horizontal () MAP transmission rates are described in Equations (3.1) and (3.2), 
respectively. 
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CHAPTER 4 
DISSERTATION CONCLUSION 
 
Worldwide, infectious diseases in livestock play a critical role in the profitability of an individual 
farm, the survival of the livestock industry itself, and international trade and trade policies. 
Besides their direct economic effect on a nation's economy, some infectious animal diseases are 
linked to diseases in humans, increasing the critical need to identify cost-effective control 
programs. Although economic models are available to examine the economics of animal diseases 
and their control strategies, they exhibit limitations in their ability to incorporate the complexity 
inherent in disease-specific epidemiology in livestock. Therefore, the main objective of this 
dissertation was to create and empirically apply a control model to examine the economics of 
infectious disease control in livestock, using Mycobacterium avium ssp. paratuberculosis (MAP) 
and Johne’s disease (JD) control in dairy herds as its paradigm.  
 The conceptual model in Chapter 2 represents an animal compartment model which 
allows animal herd dynamics within a herd or region to be accounted for by placement into 
different compartments according to their characteristics such as production- and infection-status. 
The application of this general model to JD in dairy herds illustrates its usefulness as a complex 
animal disease control model in that it presents not only the economic benefit of control 
strategies, but also the consequences of control strategies on specific disease dynamics within a 
herd. Therefore, the model is a useful tool for evaluating the economic impact of livestock 
disease and its control, and for developing a cost-effective disease control program on farms. The 
empirical results of applying the conceptual model to JD control in a dairy herd in Chapter 2 
illustrates that control of JD will significantly improve profitability for dairy producers with 
 111 
 
MAP infected herds. The empirical results also show that elimination of the disease requires a 
long-term plan with implementation of at least one of the control strategies. The most effective 
control option in reducing the infection rate in a MAP infected and therefore JD-affected herd 
being a combination of different types of control strategies.  
Chapter 3 examined the economics of potential control strategies on livestock disease 
control. Although there are many different ways to evaluate the potential economic value of a 
prospective disease control strategy, it is extremely difficult to incorporate all necessary 
evaluation tools into a single model structure. This dissertation presented a method for 
examining the epidemiological impact and economic value of hypothetical Johne's disease 
vaccines in dairy herds using net present value together with economic value analysis. This was 
accomplished by creating various scenarios for the potential epidemiological impact of currently 
existing and to be developed vaccines. Utilizing the empirical model presented in Chapter 2, 
economically justifiable values at which such vaccines could become economically beneficial to 
dairy producers were estimated. The empirical results in Chapter 3 show that any vaccination 
with either low or high efficacy yields a higher net present value compared to no control, while 
elimination of MAP, the causal pathogen of Johne's disease, requires a long-term plan with 
implementation of at least one of the high-efficacy vaccines. Moreover, most of the high-efficacy 
vaccines generated an even higher net present value compared to alternative controls currently 
used on farms, making future vaccinations economically attractive.  
 The models and results presented in Chapters 2 and 3 of this dissertation provide 
meaningful tools for examining the economics of infectious disease and its actual and potential 
control strategies in livestock. It must be acknowledged, however, that the potential risk of 
stochastic re-introduction of the disease (e.g., via purchased animals or humans with 
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contaminated clothing) was ignored in this dissertation. In addition, the animal disease control 
model presented did not provide the optimality conditions of either a conceptual or empirical 
model. This was due to the complexity of both the general animal compartment model and MAP 
infection dynamics within a herd. Therefore, an extension of this dissertation would be to 
develop a stochastic dynamic model for livestock disease control to illustrate the optimality 
conditions for the more realistic stochastic dynamic model. 
